

INDEPENDENT AUDITOR'S REPORT

To the Members of Alivira Animal Health Limited

Report on the Audit of the Standalone Financial Statements**Opinion**

We have audited the accompanying standalone financial statements of Alivira Animal Health Limited ("the Company"), which comprise the Balance sheet as at March 31, 2022, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013, as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion


We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board report, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether such other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



Responsibilities of Management for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our



auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure 1" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - (c) The Balance Sheet, the Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;
 - (e) On the basis of the written representations received from the directors as on March 31, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022 from being appointed as a director in terms of Section 164 (2) of the Act;
 - (f) With respect to the adequacy of the internal financial controls with reference to these standalone financial statements and the operating effectiveness of such controls, refer to our separate Report in "Annexure 2" to this report;
 - (g) In our opinion, the managerial remuneration for the year ended March 31, 2022 has been paid / provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act;
 - (h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:



S R B C & CO LLP

Chartered Accountants

- i. The Company has disclosed the impact of pending litigations on its financial position in its standalone financial statements – Refer Note 42 to the standalone financial statements;
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv.
 - a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the note 50 to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - b) The management has represented that, to the best of its knowledge and belief no funds have been received by the Company from any persons or entities, including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - c) Based on such audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.
- v. No dividend has been declared or paid during the year by the Company.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003



per **Anil Jobanputra**

Partner

Membership Number: 110759

UDIN: 22110759AJPTLH1311

Place of Signature: Mumbai

Date: May 25, 2022



ANNEXURE 1 TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF ALIVIRA ANIMAL HEALTH LIMITED

(Referred to in paragraph 1, under 'Report on Other Legal and Regulatory Requirements' section of our Report of even date)

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangibles assets.

(b) All Property, Plant and Equipments have not been physically verified by the management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

(c) The title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) are held in the name of the Company.

(d) The Company has not revalued its Property, Plant and Equipment (including Right of use assets) or intangible assets during the year ended March 31, 2022.

(e) There are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year. In our opinion the coverage and the procedure of such verification by the management is appropriate.


(b) As disclosed in note 23 to the financial statements, the Company has been sanctioned working capital limits in excess of Rs. five crores in aggregate from banks during the year on the basis of security of current assets of the Company. Based on the records examined by us in the normal course of audit of the financial statements, the quarterly returns/statements (including revised) filed by the Company with such banks and financial institutions are in agreement with the books of accounts of the Company.

(iii) (a) During the year the Company has provided loans, and stood guarantee to companies as follows:

(Rs. in million)		
Particulars	Guarantees	Loans
Aggregate amount provided during the year		
- Subsidiary	711.83	454.24
Balance outstanding as at balance sheet date in respect of above cases		
- Subsidiary	1,564.06	1,756.79
- Holding Company	380.00	

(b) During the year the investments made, guarantees provided and the terms and conditions of the grant of all loans and guarantees to companies are not prejudicial to the Company's interest.

(c) In respect of loan granted to companies, the schedule of repayment of principal and payment of interest has not been stipulated in the agreement. Hence, we are unable to make a specific comment on the regularity of repayment of principal and payment of interest in respect of such loan.



SRBC & CO LLP

Chartered Accountants

- (d) There are no amounts of loans granted to companies which are overdue for more than ninety days.
- (e) There were no loans or advance in the nature of loan granted to companies which was fallen due during the year, that have been renewed or extended or fresh loans granted to settle the overdues of existing loans given to the same parties.
- (f) As disclosed in note 7 to the financial statements, the Company has granted loans repayable on demand to companies. Of these following are the details of the aggregate amount of loans or advances in the nature of loans granted to related parties as defined in clause (76) of section 2 of the Companies Act, 2013:

Particulars	Amount (Rs. in million)
Aggregate amount of loans - Repayable on demand	454.24
Percentage of loans to the total loans	100%

- (iv) There are no loans, investments, guarantees, and security in respect of which provisions of sections 185 and 186 of the Companies Act, 2013 are applicable and accordingly, the requirement to report on clause 3(iv) of the Order is not applicable to the Company.
- (v) The Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Companies Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under section 148(1) of the Companies Act, 2013, related to the manufacture of animal health products, and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
- (vii) (a) The Company is generally regular in depositing with appropriate authorities undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, cess and other statutory dues applicable to it. According to the information and explanations given to us and based on audit procedures performed by us, no undisputed amounts payable in respect of these statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.
- (b) There are no dues of goods and services tax, provident fund, employees' state insurance, income tax, goods and service tax and other statutory dues which have not been deposited on account of any dispute.
- (viii) The Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.
- (ix) (a) The Loan amounting to Rs. 1,756.79 million is repayable on demand and terms and conditions for payment of interest thereon has not been stipulated. Such loan and interest thereon have not been demanded for repayment during the relevant financial year. The Company has not defaulted in repayment of other borrowings or payment of interest thereon to any lender.
- (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.



SRBC & CO LLP

Chartered Accountants

- (c) The Term loans were applied for the purpose for which the loans were obtained.
- (d) On an overall examination of the financial statements of the Company, no funds raised on short-term basis have been used for long-term purposes by the Company.
- (e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
- (f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies. Hence, the requirement to report on clause (ix)(f) of the Order is not applicable to the Company.
- (x) (a) The Company has not raised any money during the year by way of initial public offer / further public offer (including debt instruments) hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company.

(b) The Company has not made any preferential allotment or private placement of shares /fully or partially or optionally convertible debentures during the year under audit and hence, the requirement to report on clause 3(x)(b) of the Order is not applicable to the Company.
- (xi) (a) No material fraud by the Company or on the Company has been noticed or reported during the year.

(b) During the year, no report under sub-section (12) of section 143 of the Companies Act, 2013 has been filed by cost auditor, secretarial auditor or by us in Form ADT – 4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.
- (xii) The Company is not a nidhi Company as per the provisions of the Companies Act, 2013. Therefore, the requirement to report on clause 3(xii)(a) (b) and (c) of the Order is not applicable to the Company.
- (xiii) Transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.
- (xiv) (a) The Company has an internal audit system commensurate with the size and nature of its business.

(b) The internal audit reports of the Company issued till the date of the audit report, for the period under audit have been considered by us.
- (xv) The Company has not entered into any non-cash transactions with its directors or persons connected with its directors and hence requirement to report on clause 3(xv) of the Order is not applicable to the Company.
- (xvi) (a) The provisions of section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi)(a) of the Order is not applicable to the Company.



S R B C & C O L L P

Chartered Accountants

- (b) The Company has not conducted any Non-Banking Financial or Housing Finance activities without obtained a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934.
- (c) The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi) of the Order is not applicable to the Company.
- (d) There is no Core Investment Company as a part of the Group, hence, the requirement to report on clause 3(xvi) of the Order is not applicable to the Company.
- (xvii) The Company has not incurred cash losses in the current and immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year and accordingly requirement to report on Clause 3(xviii) of the Order is not applicable to the Company.
- (xix) On the basis of the financial ratios disclosed in note 49 to the financial statements, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) (a) In respect of other than ongoing projects, there are no unspent amounts that are required to be transferred to a fund specified in Schedule VII of the Companies Act (the Act), in compliance with second proviso to sub section 5 of section 135 of the Act. This matter has been disclosed in note 44 to the financial statements.
- (b) All amounts that are unspent under section (5) of section 135 of Companies Act, pursuant to any ongoing project, has been transferred to special account in compliance of with provisions of sub section (6) of section 135 of the said Act. This matter has been disclosed in note 44 to the financial statements.

For **S R B C & C O L L P**

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003



per **Anil Jobanputra**

Partner

Membership Number: 110759

UDIN: 22110759AJPTLH1311

Place of Signature: Mumbai

Date: May 25, 2022



ANNEXURE 2 TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF ALIVIRA ANIMAL HEALTH LIMITED
Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to financial statements of Alivira Animal Health Limited ("the Company") as of March 31, 2022 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility


Our responsibility is to express an opinion on the Company's internal financial controls with reference to these financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, as specified under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both issued by ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to these financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to these financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to these financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to these financial statements.

Meaning of Internal Financial Controls With Reference to these Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the



S R B C & CO LLP

Chartered Accountants

company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls With Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003



per **Anil Jobanputra**


Partner

Membership Number: 110759

UDIN: 22110759AJPTLH1311

Place of Signature: Mumbai

Date: May 25, 2022



Alivira Animal Health Limited
Balance Sheet as at 31st March 2022
All amounts are in Rs. million unless otherwise stated

	Notes	As at 31 March 2022	As at 31 March 2021
A. ASSETS			
1 Non-current assets			
(a) Property, plant and equipment	3.a	1,012.77	933.18
(b) Right-of-use assets	3.b	483.34	505.56
(c) Capital work-in-progress	3.c	38.15	225.18
(d) Goodwill	4	68.89	68.89
(e) Intangible assets	5.a	9.82	18.20
(f) Intangible assets under development	5.b	2.83	-
(g) Financial assets			
(i) Investments in subsidiary	6	3,682.00	3,562.63
(ii) Loans	7	1,756.79	1,254.19
(iii) Other financial assets	8	16.85	21.78
(h) Deferred tax assets (net)	9	101.13	133.64
(i) Income tax assets (net)	9.a	37.81	39.44
(j) Other non-current assets	10	5.45	4.13
Total non-current assets		7,215.83	6,766.82
2 Current assets			
(a) Inventories	11	882.97	682.45
(b) Financial assets			
(i) Trade receivables	12	1,064.01	837.11
(ii) Cash and cash equivalents	13	26.09	13.54
(iii) Bank balances other than (ii) above	14	16.37	21.17
(iv) Other financial assets	15	8.37	80.70
(c) Other current assets	16	174.51	112.79
Total current assets		2,172.32	1,747.76
Total Assets		9,388.15	8,514.58
B. EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	17	477.76	477.76
(b) Other equity	18	4,750.38	4,474.49
Total equity		5,228.14	4,952.25
II Liabilities			
1 Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	19	2,428.87	2,207.81
(ii) Lease liabilities	20	101.42	119.06
(b) Provisions	21	49.89	42.37
(c) Other non-current liabilities	22	1.27	0.63
Total non-current liabilities		2,581.45	2,369.87
2 Current liabilities			
(a) Financial liabilities			
(i) Borrowings	23	738.04	381.73
(ii) Lease liabilities	26	4.15	4.09
(iii) Trade payables			
Total outstanding dues of micro enterprises and small enterprises	24	57.87	38.97
Total outstanding dues of creditors other than micro enterprises and small enterprises	24	704.83	674.93
(iv) Other financial liabilities	25	22.69	18.16
(b) Provisions	27	19.71	28.15
(c) Other current liabilities	28	31.27	46.43
Total current liabilities		1,578.56	1,192.46
Total Liabilities		4,160.01	3,562.33
Total Equity and Liabilities		9,388.15	8,514.58


Significant accounting policies
The accompanying notes are integral part of these financial statements

2

As per our report of even date

For S R B C & CO LLP
Chartered Accountants
ICAI firm registration number : 324982E / E300003


Per Anil Jobanputra
Partner
Membership No: 110759



Mumbai, 25 May 2022

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


Rajaram Narayanan
Managing Director &
Chief Executive Officer
DIN: 02977405


Tushar Mistry
Chief Financial Officer


Sharat Narsapur
Joint Managing
Director
DIN: 02808651


Abhishek Joshi
Company Secretary
Membership No: AG1862



Alivira Animal Health Limited
Statement of Profit and Loss for year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated except for earnings per share information

	Notes	Year ended 31 March 2022	Year ended 31 March 2021
1 Revenue from operations	29	4,784.88	4,233.60
2 Other income	30	172.89	127.04
3 Total income (1+2)		4,957.77	4,360.64
4 Expenses			
(a) Cost of materials consumed	31.a	1,362.64	1,101.28
(b) Purchases of stock-in-trade	31.b	1,529.28	1,467.95
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	31.c	(111.99)	(214.87)
(d) Employee benefits expense	32	682.02	508.19
(e) Finance costs	33	227.89	246.09
(f) Depreciation and amortisation expenses	34	203.11	204.11
(g) Other expenses	35	858.38	732.22
Total expenses (4)		4,751.33	4,044.97
5 Profit before exceptional items and tax (3-4)		206.44	315.67
6 Exceptional items (6)	36	-	24.35
7 Profit before tax (5-6)		206.44	291.32
8 Tax expense / (credits)	37		
(1) Current tax		35.82	47.99
(2) Current tax of earlier years		-	(3.46)
(3) Deferred tax		31.16	(51.25)
Total tax expense/ (credits) (8)		66.98	(6.72)
9 Profit after tax (7-8)		139.46	298.04
10 Other comprehensive income	18		
Items that will not be reclassified to profit or loss			
(a) Re-measurement gain on defined benefit plans		3.79	3.47
(b) Income tax relating to items that will not be reclassified to profit or loss		(1.33)	(1.21)
Total other comprehensive income (net of tax) (10)		2.46	2.26
11 Total comprehensive income for the year, net of tax (9+10)		141.92	300.30
Earnings per equity share (Face value of share - Rs 10 each)			
(1) Basic (in Rs.)	38	2.92	6.24
(2) Diluted (in Rs.)	38	2.92	6.24
Significant accounting policies	2		
The accompanying notes are integral part of these financial statements			

As per our report of even date

For S R B C & CO LLP
Chartered Accountants
ICAI firm registration number : 324982E / E300003



Per Anil Jobanputra
Partner
Membership No: 110759




Mumbai, 25 May 2022


FOR AND ON BEHALF OF THE BOARD OF DIRECTORS


Rajaram Narayanan
Managing Director &
Chief Executive Officer
DIN:02977405


Tushar Mistry
Chief Financial Officer


Sharat Narsapur
Joint Managing
Director
DIN:02808651


Abhishek Joshi
Company Secretary
Membership No- A61862



Alivira Animal Health Limited
Statement of cash flows for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

	Year ended 31 March 2022	Year ended 31 March 2021
Cash flow from operating activities		
Net Profit before tax and exceptional items	206.44	315.67
Adjustments for:		
Depreciation and amortisation expenses	203.11	204.11
Bad trade receivables/advances written off	1.42	-
Amortisation of financial guarantee obligations	10.21	3.69
Provision for trade receivable written back	(4.81)	(0.80)
Share based payments to employees	2.61	36.68
Cancellation of Lease	(3.89)	-
Unrealised forex loss / (gain) (net)	(47.50)	2.25
Loss / (Profit) on sale of property, plant and equipment	(0.17)	(0.14)
Finance costs	217.68	246.09
Gain on sale of investments	-	(5.23)
Corporate guarantee commission	(6.79)	(2.81)
Interest income	(32.32)	(17.65)
Operating profit before working capital changes	545.99	781.86
Changes in working capital		
(Increase) / Decrease in trade receivables, loans and advances and other assets	(208.01)	154.00
(Increase) / decrease in inventories	(200.52)	(221.42)
(Increase) / decrease in margin money and other deposits	4.41	62.21
Increase / (decrease) in trade payables, other payables and provisions	51.13	185.21
Net change in working capital	(352.99)	180.00
Cash generated from operations	193.00	961.86
Income taxes paid (net)	(34.19)	(114.00)
Net cash generated from operating activities	A 158.81	847.86
Cash flow from investing activities		
Purchase of property, plant and equipment's and intangible assets	(80.20)	(244.98)
Proceeds from disposal of property, plant and equipments	0.25	1.95
Redemption of mutual funds	-	156.56
Loan given to subsidiary company	(426.62)	(939.08)
Interest received	1.72	3.63
Net cash used in investing activities	B (504.85)	(1,021.92)
Cash flow from financing activities		
(Repayment)/Proceeds of short-term borrowings (net)	356.27	(110.69)
Loan received from related parties (net)	63.00	1,534.50
Payment of principal portion of lease liabilities (Refer 48)	(3.91)	(3.14)
Repayments of long-term borrowings	(1.28)	(1,198.91)
Interest and other borrowing costs	(55.49)	(144.09)
Net cash generated from financing activities	C 358.59	77.67
Net increase in cash and cash equivalents during the year	(A+B+C) 12.55	(96.39)
Cash and cash equivalents at the beginning of the year (refer note 13)	13.54	109.93
Cash and cash equivalents at the end of the year (refer note 13)	26.09	13.54

Note: The statement of cash flows has been prepared under the indirect method, as set out in Ind AS 7 'Statement of Cash Flows'.

Reconciliation of liabilities arising from financing activities

As at 31st March 2022	Opening Balance	Cash Flows	Non-Cash Changes	Balance
Borrowings and Lease liabilities	2,712.69	414.08	145.71	3,272.48
Total liabilities from financing activities	2,712.69	414.08	145.71	3,272.48

As at 31st March 2021	Opening Balance	Cash Flows	Non - Cash Changes	Balance
Borrowings and Lease liabilities	2,391.18	221.76	99.75	2,712.69
Total liabilities from financing activities	2,391.18	221.76	99.75	2,712.69

Significant accounting policies (Refer Note 2)

The accompanying notes are integral part of these financial statements

As per our report of even date

For S R B C & CO LLP
Chartered Accountants
ICAI firm registration number : 324982E / E300003

Per Anil Jobanputra
Partner
Membership No: 110759



Mumbai, 25 May 2022

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

Rajaram Narayanan
Managing Director &
Chief Executive Officer
DIN:02977405

Sharat Narsapur
Joint Managing
Director
DIN:02808651

Tushar Mistry
Chief Financial Officer

Abhishek Joshi
Company Secretary
Membership No- A61862



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

1. CORPORATE INFORMATION

Alivira Animal Health Limited (the “Company”) is a Company incorporated and domiciled in India and has its registered office located at 301, 3rd Floor, Dosti Pinnacle, Plot No. E7 Road No. 22, Wagle Industrial Estate, Thane (W), Maharashtra - 400604, India. The Company is an integrated veterinary Active Pharmaceutical Ingredient (API) and Finished dosage formulations.

2. SIGNIFICANT ACCOUNTING POLICIES

2.1 Statement of Compliance

The financial statements have been prepared in accordance with Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time and presentation requirements of Division II of Schedule III to the Companies Act, 2013.

2.2 Basis of preparation and presentation

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. Fair value for measurement and / or disclosure purposes in these financial statements is determined on such a basis, except for

- Share based payment transaction as defined in Ind AS 102 – Share based payment.
- Leasing transaction as defined in Ind AS 116 – Leases.
- Measurement that has some similarities to fair value but are not fair value, such as ‘Net Realisable Value’ as defined in Ind AS 2 – Inventories and value in use as defined in Ind AS 36- Impairment of Assets.

The financial statements have been prepared on accrual and going concern basis. The accounting policies are applied consistently to all the periods presented in the financial statements. All assets and liabilities have been classified as current or non-current as per the Company’s normal operating cycle. Based on the nature of products and the time between acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current or non-current classification of assets and liabilities.

2.3 Functional and presentation currency

These financial statements are presented in Indian Rupees (INR), which is the Company’s functional currency. All financial information presented in INR has been rounded to the nearest million (up to two decimals), except otherwise stated.

2.4 Significant Accounting Policies

(i) Revenue recognition

Sale of good

Revenue from sale of products is presented in the income statement within Revenue from operations. The Company presents revenue net of indirect taxes in its statement of profit and loss. Sale of products comprise revenue from sales of products, net of sales returns, rebates, incentives, and customer discounts.

Revenue is recognized when the Company transfers control over the product to the customers; control of a product refers to the ability to direct the use of and obtain substantially all of the remaining benefits from that asset. Performance obligations are satisfied at one point in time, typically on delivery. Most of the revenue earned by the Company is derived from the satisfaction of a single performance obligation for each contract which is the sale of products.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

Sales are measured at the fair value of consideration received or receivable. The amounts of rebates / incentives are estimated and accrued on each of the underlying sales transactions recognized. Returns and customer discounts are recognized in the period in which the underlying sales are recognized. The amount of sales returns is calculated on the basis of management's best estimate of the amount of product that will ultimately be returned by customers.

Contract assets

A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognized for the said earned consideration.

Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Company has received consideration (or an amount of consideration is due) from the customer. If a customer pays consideration before the Company transfers goods or services to the customer, a contract liability is recognised when the payment is received from customer or due, whichever is earlier. Contract liabilities are recognised as revenue when the Company performs under the contract.

Services

Income is recognised when the services are completed as per the terms of the agreement and when no significant uncertainty as to its determination or realisation exists.

Export entitlements income

Export entitlements from Government authorities are recognised in the statement of profit and loss when the right to receive credit as per the terms of the scheme is established in respect of the exports made by the Company, and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.

Interest and dividend income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable.

Dividend income from investments is recognised when the Company's right to receive payment has been established.

(ii) Leases

The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Company as a lessee

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

i) Right-of-use assets

The Company recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the of the lease term.

If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

The right-of-use assets are also subject to impairment. Refer to the accounting policies (xii) Impairment of non-financial assets. Below table mentions



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

Nature of the Assets	Lease term
Buildings	20-99
Land	80-99

ii) Lease liabilities

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset.

(iii) Foreign currency transactions and translation

Transactions in currencies other than the entity's functional currency (foreign currencies) are recognized at the rates of exchange prevailing at the dates of the transactions.

At the end of each reporting period, monetary items denominated in foreign currencies are translated at the rates prevailing at that date. Exchange differences arising on settlement or translation of monetary items are recognized in the statement of profit and loss in the year in which it arises.

Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are translated to the functional currency at the exchange rate at the date that the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.

Exchange difference on capital expenditure is capitalised only to the extent attributable to borrowing costs and balance is charged to the standalone statement of profit and loss.

(iv) Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or erection of qualifying assets are added to the cost of those assets, until such time that the assets are substantially ready for their intended use. Qualifying assets are assets which take a substantial period of time to get ready for their intended use or sale.

Interest income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalization.

All other borrowing costs are recognised in the statement of profit and loss in the period in which they are incurred.

(v) Employee Benefits

a. Defined Contribution Plans:


The Company has defined contribution plans for post-employment benefits in the form of provident fund which is administered through Government of India. Provident fund is classified as defined contribution plans as the Company has no further obligation beyond making the contributions. The company's contributions to defined contribution plans are charged to the statement of profit and loss as and when employee renders related service.

b. Defined benefit plans

Payments to defined benefit plans are recognised as an expense when employees have rendered service entitling them to the contributions.

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The Company's gratuity scheme is in the nature of defined benefit plan.

The gratuity scheme is partly funded by the Company with Life Insurance Corporation of India.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

For defined benefit plans, the cost of providing benefit is determined using projected unit credit method, with actuarial valuation being carried out at the end of each financial year. Re-measurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding net interest), is reflected immediately in the balance sheet with a charge or credit recognised in other comprehensive income in the period in which they occur. Re-measurement recognised in other comprehensive income is reflected immediately in retained earnings and is not reclassified to the statement of profit and loss. Past service cost is recognized in the statement of profit and loss in the period of a plan amendment. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset. Defined benefit costs are categorized as follows:

- service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements);
- net interest expense or income; and
- re-measurement gain / (loss).

The Company presents the service cost of defined benefit plan in the line item 'Employee benefits expense' and the net interest expense or income in the line item 'Finance costs' of the statement of profit and loss. Curtailment gains and losses are accounted for as past service costs. The retirement benefit obligation recognised in the balance sheet represents the actual deficit or surplus in the Company's defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or reductions in future contributions to the plans.

Short-term employee benefits

A liability is recognised for short-term employee benefit obligations in respect of wages and salaries, medical and leave travel in the period the related service is rendered at the undiscounted amount of the benefits expected to be paid in exchange for that service.

Other employee benefits

Other employee benefits comprise of leave encashment, which is provided for, based on the actuarial valuation carried out as at the end of the year. Liabilities recognised in respect of other employee benefits are measured at the present value of the estimated future cash outflows expected to be made by the Company in respect of services provided by employees up to the reporting date.

(vi) **Taxation**

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. Provision for current tax is made at the rate of tax as applicable for the income of the previous year as defined under Income Tax Act, 1961.

Minimum Alternate Tax ('MAT') paid in accordance to the tax laws, which gives rise to future economic benefits in the form of adjustment of future tax liability is recognised as an asset in the balance sheet when it is probable that the future economic benefit associated with it will flow to the Company and asset can be measured reliably.

Current tax assets and current tax liabilities are offset when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle the asset and the liability on a net basis.

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and considers whether it is probable that a taxation authority will accept an uncertain tax treatment.

The Company applies significant judgement in identifying uncertainties over income tax treatments. The Company reflects the effect of uncertainty for each uncertain tax treatment by using either most likely method or expected value method, depending on which method predicts better resolution of the treatment.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

b) Deferred tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from the initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, deferred tax liabilities are not recognised if the temporary difference arises from the initial recognition of goodwill.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the end of each reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and deferred tax liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities; and the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority.

No deferred tax (asset or liability) is recognized in respect of temporary differences which reverse during the tax holiday period, to the extent the Company's gross total income is subject to the deduction during the tax holiday period. Deferred tax in respect of temporary differences which reverse after the tax holiday period is recognized in the year in which the temporary differences originate.

Deferred tax relating to items recognised outside the statement of profit or loss is recognised either in other comprehensive income or in equity.

(vii) Property, plant and equipment

a. Recognition and measurement

Property, plant, and equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment losses, if any.

Cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for its intended use. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use. Capital work in process is stated at cost net of accumulated impairment cost if any.

Capital work in progress is stated at cost, net of accumulated impairment loss, if any.

When parts of an item of property, plant and equipment have significant cost in relation to total cost and different useful lives, they are recognized and depreciated separately.

Depreciation is recognised to write off the cost of assets (other than freehold land) less their residual values, using the straight-line method, over the useful lives specified in Schedule II to the Companies Act, 2013 except for the following items, where useful life estimated on technical assessment, past trends and differ from those provided in Schedule II of the Companies Act, 2013.

Nature of the Assets	Useful life in years
Buildings	10-60
Furniture and fixtures	5-10
Office equipment's	2-5
Computers	1-6
Plant and machinery	1-15
Vehicles	8



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimates are accounted for on a prospective basis.

Depreciation on additions / deletions to property, plant and equipment is provided prorata from the month of addition / till the month of deletion.

b. Subsequent costs

The cost of replacing part of an item of property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The costs of repairs and maintenance are recognized in the statement of profit and loss as incurred.

c. Derecognition of Property, Plant & Equipment

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in the statement of profit and loss.

(viii) Intangible assets

a. Intangible assets acquired separately

Intangible assets that are acquired by the Company, which have finite useful lives, are measured at cost less accumulated amortization and accumulated impairment losses. Amortisation is recognised on straight-line basis over the estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each financial year, with the effect of any changes in estimate being accounted for on a prospective basis. Cost includes any directly attributable incidental expenses necessary to make the assets ready for use.

b. Internally-generated intangible asset - Research and Development expenditure

Expenditure on research activities is recognised as an expense in the year in which it is incurred.

An internally-generated intangible asset arising from development is recognised if, and only if, all of the following have been demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible asset;
- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognised for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognised, development expenditure is recognised in the statement of profit and loss in the period in which it is incurred.

Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.

c. Useful lives of intangible assets

Estimate useful lives of the intangible assets are as follow:

Nature of the Assets	Useful life in years
Marketing rights	5
Intellectual property rights	5
Software	3-5



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

d. Subsequent costs

Subsequent costs are capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated intangibles, are recognised in the statement of profit and loss as incurred.

e. Derecognition of intangible assets

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognised in the statement of profit and loss.

(ix) Inventories

Inventories are valued at the lower of cost and net realizable value.

Cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on First in First out basis (FIFO) as follows:

- (i) Raw materials, packing materials and fuel: At actual purchase cost including other cost incurred in bringing materials / consumables to their present location and condition.
- (ii) Work in process and Intermediates: At material cost, conversion costs and appropriate share of production overheads based on normal capacity.
- (iii) Finished goods: At material cost, conversion costs and an appropriate share of production overheads based on normal capacity.
- (iv) Stock-in-trade: At purchase and other costs incurred in bringing the inventories to their present location and condition.

However, materials and other items held for use in production of inventory are not written down below cost, if the finished product in which they will be used are expected to be sold at or above cost.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

(x) Provisions and contingent liabilities

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received, and the amount of the receivable can be measured reliably.

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle the obligation, or a reliable estimate of the amount cannot be made. Contingent assets are not recognized but are disclosed in the notes to financial statements when economic inflow is probable.

(xi) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

Financial assets and financial liabilities are recognised when an entity becomes a party to the contractual provisions of the instruments.

All financial instruments are initially measured at fair value. Transaction costs that are attributable to the acquisition or issue of the financial asset and financial liabilities (other than financial assets recorded at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities as appropriate, on initial recognition. Transaction cost directly attributable to the acquisition or issue of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in the statement of profit and loss.

Purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trade) are recognised on trade date.

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: non-derivative financial assets comprising amortised cost, debt instruments at fair value through other comprehensive income (FVTOCI), equity instruments at FVTOCI and fair value through profit and loss account (FVTPL), non-derivative financial liabilities at amortised cost or FVTPL and derivative financial instruments (under the category of financial assets or financial liabilities) at FVTPL.

The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

a) Non-derivative financial assets

(i) Financial assets at amortised cost

A financial asset is measured at amortised cost if both of the following conditions are met:

(a) The financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and

(b) The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial assets are measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest rate ('EIR') method, less any impairment loss.

Financial assets at amortised cost are represented by trade receivables, security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets.

(ii) Equity instruments at fair value through other comprehensive income (FVTOCI)

All equity instruments other than investments in subsidiaries are measured at fair value. Equity instruments held for trading is classified as FVTPL. For all other equity instruments, the Company may make an irrevocable election to present subsequent changes in the fair value in OCI. The Company makes such election on an instrument-by-instrument basis.

If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividend are recognised in OCI. There is no recycling of the amount from OCI to the statement of profit and loss, even on sale of the instrument. However, the Company may transfer the cumulative gain or loss within the equity.

(iii) Financial assets at fair value through profit or loss (FVTPL)

FVTPL is a residual category for financial assets. Any financial asset which does not meet the criteria for categorization as at amortised cost or as FVTOCI, is classified as FVTPL.

In addition, the Company may elect to designate the financial asset, which otherwise meets amortised cost or FVTOCI criteria, as FVTPL if doing so eliminates or significantly reduces a measurement or recognition inconsistency.

Financial assets included within the FVTPL category are measured at fair values with all changes in the statement of profit and loss.

(iv) Derecognition of financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or the financial assets is transferred, and the transfer qualifies for derecognition. On derecognition of a financial asset in its entirety, the difference between the carrying amount (measured at the date of derecognition) and the consideration received (including any new assets obtained less any new liability assumed) shall be recognised in the statement of profit and loss except for debt and equity instruments carried through FVTOCI which shall be recognised in OCI.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

b) Non-derivative financial liabilities

(i) Financial liabilities at amortised cost

Financial liabilities at amortised cost represented by trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the EIR method.

(ii) Financial liabilities at Fair value through profit or loss (FVTPL)

Financial liabilities at FVTPL are measured at fair value with all changes recognised in the statement of profit and loss.

(iii) Derecognition of financial Liabilities

The Company derecognises financial liabilities only when the obligations are discharged, cancelled, or have expired. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in statement of profit and loss.

c) Derivative financial instruments

The Company holds derivative financial instruments such as foreign exchange forward contracts to mitigate the risk of changes in foreign exchange rates on foreign currency assets or liabilities. Derivatives are recognized and measured at fair value. Attributable transaction cost is recognized in the statement of profit and loss.

(xii) Impairment

Financial assets

In accordance with Ind AS 109 – Financial Instruments, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

(i) All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument.

(ii) Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

As a practical expedient, the Company uses a provision matrix to determine impairment loss on portfolio of its trade receivable. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable and is adjusted for forward- looking estimates. At every reporting date, the historical observed default rates are updated and changes in forward-looking estimates are analyzed.


ECL impairment loss allowance (or reversal) recognised during the period is recognised as income / expense in the statement of profit and loss. This amount is reflected under the head other expenses in the statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortised cost, contractual revenue receivable:

ECL is presented as an allowance, i.e., as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

Non-financial assets

The Company assesses at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an assets or cash-generating unit's (CGU) fair value less costs of disposal and its value in use.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

An impairment loss is recognised in the Statement of Profit and Loss to the extent, asset's carrying amount exceeds its recoverable amount. The recoverable amount is higher of an asset's fair value less cost of disposal and value in use.

Value in use is based on the estimated future cash flows, discounted to their present value using pre-tax discount rate that reflects current market assessments of the time value of money and risk specific to the assets. For the purpose of assessing impairment, assets are grouped at the lowest levels into cash generating units for which there are separately identifiable cash flows.

An impairment loss recognised in prior years are reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment had been recognised in previous years.

(xiii) Earnings per share

Basic EPS is computed by dividing the net profit for the period attributable to the equity shareholders by the weighted average number of equities shares outstanding during the period.

Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

(xiv) Cash and cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

(xv) Share-based compensation

Employee stock option schemes of holding company provides for grant of equity shares of SeQuent Scientific Limited (the holding company) to employees of the Company.

Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. Details regarding the determination of the fair value of equity-settled share-based transactions are set out in note 46.

The fair value determined at the grant date of the equity-settled share-based payments is expensed on a systematic basis over the vesting period, based on the Company's estimate of equity instruments that will eventually vest, with a corresponding increase in equity. At the end of each reporting period, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in the statement of profit and loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the equity-settled employee benefits reserve.

(xvi) Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

(xvii) Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current / non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle,
- Held primarily for the purpose of trading,
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

It is expected to be settled in normal operating cycle

- It is held primarily for the purpose of trading,
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

(xviii) Exceptional Items

Exception items include income or expense that are considered to be part of ordinary activities, however, are of such significance and nature that separate disclosure enables the user of Financial Statements to understand the impact in a more meaningful manner. Exceptional items are identified by virtue of either their size or nature so as to facilitate comparison with prior periods and to assess underlying trends in the financial performance of the Company.

2.A Use of estimates and management judgments

In application of the accounting policies, which are described in note 2, the management of the company is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised if the revision affects only that period, or in the period of revision and future periods if the revision affects both current and future periods. In particular, information about significant areas of estimation, uncertainty and critical judgements used in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is included in the following notes:

1. Useful life of property, plant and equipment and intangible assets

The useful life of the assets is determined in accordance with Schedule II of the Companies Act, 2013. In cases, where the useful life is different from that or is not prescribed in Schedule II, it is based on technical advice, taking into account the nature of the asset, the estimated usage of the asset, the operating conditions of the asset, past history of replacement, anticipated technological changes, manufacturers warranties and maintenance.

2. Impairment

An impairment loss is recognised for the amount by which an asset's / investments or cash-generating unit's carrying amount exceeds its recoverable amount. To determine the recoverable amount, management estimates expected discounted future cash flows from each asset or cash-generating unit.

3. Deferred Tax

Deferred income tax liabilities are recognized for all taxable temporary differences. Deferred income tax asset is recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022

4. Fair Value

Management uses valuation techniques in measuring the fair value of financial instruments where active market quotes are not available. In applying the valuation techniques, management makes maximum use of market inputs and uses estimates and assumptions that are, as far as possible, consistent with observable data that market participants would use in pricing the instrument. Where applicable data is not observable, management uses its best estimate about the assumptions that market participants would make. These estimates may vary from the actual prices that would be achieved in an arm's length transaction at the reporting date.

5. Post-retirement benefit plans

The obligation arising from the defined benefit plan is determined on the basis of actuarial assumptions which include discount rate, trends in salary escalation and vested future benefits and life expectancy. The discount rate is determined with reference to market yields at the end of the reporting period on the government bonds.

6. Provisions and contingencies

The recognition and measurement of other provisions are based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the reporting date. The actual outflow of resources at a future date may therefore vary from the figure estimated at end of financial year.

7. Share based payments

Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including the expected life of the share option, volatility and dividend yield and making assumptions about them. For the measurement of the fair value of equity-settled transactions with employees at the grant date, the Company uses black Scholes model Employee Share Option Plan.




Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

3.a Property, plant and equipment

Cost	Buildings	Furniture & fixtures	Office equipments	Computers	Plant & machinery	Vehicles	Total
Balance as on 01 April 2020	541.36	9.94	7.87	12.03	1,166.65	5.43	1,743.28
Additions	12.89	0.49	0.09	4.72	21.09	-	39.28
Deletions	-	0.38	0.48	1.85	4.84	0.87	8.42
Balance as on 31 March 2021	554.25	10.05	7.48	14.90	1,182.90	4.56	1,774.14
Additions	35.93	0.98	0.65	11.70	212.70	-	261.96
Deletions	0.01	0.02	0.03	0.15	0.30	-	0.51
Balance as on 31 March 2022	590.17	11.01	8.10	26.45	1,395.30	4.56	2,035.59
Accumulated depreciation							
Balance as on 01 April 2020	104.12	4.29	6.50	9.03	577.29	1.87	703.10
Depreciation expense for the year (refer note 34)	22.23	1.15	0.62	2.26	117.33	0.89	144.48
Deletions	-	0.38	0.48	1.72	3.17	0.87	6.62
Balance as on 31 March 2021	126.35	5.06	6.64	9.57	691.45	1.89	840.96
Depreciation expense for the year (refer note 34)	25.10	1.15	0.67	3.24	151.56	0.57	182.29
Deletions	0.01	0.02	0.03	0.15	0.22	-	0.43
Balance as on 31 March 2022	151.44	6.19	7.28	12.66	842.79	2.46	1,022.82
Carrying amount							
Balance as on 31 March 2021	427.90	4.99	0.84	5.33	491.45	2.67	933.18
Balance as on 31 March 2022	438.73	4.82	0.82	13.79	552.51	2.10	1,012.77

Notes:


- Title deeds of all the immovable properties are held in the name of the Company.
- Refer note 19 for charge created on the assets.
- Refer note 42 for capital commitments.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

3.b Right-of-Use Assets

Cost	ROU- Land	ROU- Buildings	Total
Balance as on 01 April 2020	453.70	77.33	531.03
Additions	-	-	-
Deletions	-	-	-
Balance as on 31 March 2021	453.70	77.33	531.03
Additions	-	-	-
Deletions	-	13.54	13.54
Balance as on 31 March 2022	453.70	63.79	517.49
Accumulated depreciation			
	ROU- Land	ROU- Buildings	Total
Balance as on 01 April 2020	5.00	7.74	12.74
Depreciation expense for the year (refer note 34)	5.00	7.73	12.73
Deletions	-	-	-
Balance as on 31 March 2021	10.00	15.47	25.47
Depreciation expense for the year (refer note 34)	5.00	7.45	12.45
Deletions	-	3.77	3.77
Balance as on 31 March 2022	15.00	19.15	34.15
Carrying amount			
	ROU- Land	ROU- Buildings	Total
Balance as on 31 March 2021	443.70	61.86	505.56
Balance as on 31 March 2022	438.70	44.64	483.34



3.c Capital-work-in progress

i. Ageing schedule as on 31.03.2022

Capital-work-in progress	Amount in CWIP for a period of			Total
	Less than 1 year	1-2 years	2-3 years	
Projects in progress	38.15	-	-	38.15
Projects temporarily suspended	-	-	-	-

ii. Completion schedule for capital work-in-progress whose completion is overdue or has exceeded its cost compared to its original plan as on 31.03.2022


CWIP	To be completed in			Total
	Less than 1 year	1-2 years	2-3 years	
Projects in progress	-	-	-	-

iii. Ageing schedule as on 31.03.2021

CWIP	Amount in CWIP for a period			Total
	Less than 1 year	1-2 years	2-3 years	
Projects in progress	76.44	148.74	-	225.18
Projects temporarily suspended	-	-	-	-

iv. Completion schedule for capital work-in-progress whose completion is overdue or has exceeded its cost compared to its original plan as on 31.03.2021

Capital-work-in progress	To be completed in			Total
	Less than 1 year	1-2 years	2-3 years	
Projects in progress	-	-	-	-



4 Goodwill

4.1 Allocation of goodwill to cash-generating units

Goodwill has been allocated for impairment testing purposes to the following cash-generating units. The carrying amount of goodwill allocated to cash-generating units is as follows:

	As at 31 March 2022	As at 31 March 2021
Lyka Business	33.85	33.85
Veterinary Formulation Division	35.04	35.04
Total	68.89	68.89

Goodwill is monitored by the management of the Company at each cash-generating unit (CGU). The Company tests Goodwill for impairment on an annual basis. The recoverable amounts have been determined based on value in use calculations which uses cash flow projections based on financial budgets covering a period of five years. The planning horizon reflects the assumptions for short to mid-term market developments. The key assumptions used for the calculations were as follows:

	As at 31 March 2022	As at 31 March 2021
Discount rate	17.76%	17.76%
Long term growth rate	4%	4%

The management of the company believes that any reasonably possible change in the key assumption on which recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount of the cash-generating unit. The goodwill is tested for impairment and accordingly no impairment charges were identified for year ended 31 March 2022. (31 March 2021 : Nil).

5 Intangible assets

5.a. Intangible assets

Cost	Software	Intellectual property rights	Marketing rights	Total
Balance as on 01 April 2020	23.39	322.98	389.26	735.63
Additions during the year	0.60	-	-	0.60
Balance as on 31 March 2021	23.99	322.98	389.26	736.23
Additions during the year	-	-	-	-
Balance as on 31 March 2022	23.99	322.98	389.26	736.23

Accumulated amortisation	Software	Intellectual property rights	Marketing rights	Total
Balance as on 01 April 2020	12.96	290.57	367.60	671.13
Amortisation expense for the year (refer note 34)	4.68	20.56	21.66	46.90
Balance as on 31 March 2021	17.64	311.13	389.26	718.03
Amortisation expense for the year (refer note 34)	4.72	3.66	-	8.37
Balance as on 31 March 2022	22.36	314.79	389.26	726.41

Carrying amount	Software	Intellectual property rights	Marketing rights	Total
Balance as on 31 March 2021	6.35	11.85	-	18.20
Balance as on 31 March 2022	1.63	8.19	-	9.82

5.b. Intangible assets under development (IAUD)

i. Ageing schedule as on 31.03.2022

Intangible assets under development	Amount in IAUD for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	2.83	-	-	-	2.83
Projects temporarily suspended	-	-	-	-	-

ii. Completion schedule for intangible assets under development whose completion is overdue or has exceeded its cost compared to its original plan as on 31.03.2022

Intangible assets under development	To be completed in				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	-	-	-	-	-



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

6	Non-current investments		As at	As at
			31 March 2022	31 March 2021
	Investments in subsidiary			
	Unquoted equity instruments - carried at cost			
	Alivira Animal Health Limited, Ireland		3,682.00	3,562.63
	13,781,275 Equity Shares of EURO 1 each fully paid-up (31 March 2021 : 13,781,275 shares) (Refer Note 39.2)			
	Total		3,682.00	3,562.63
	Aggregate carrying value of unquoted investments		3,682.00	3,562.63

7	Non-current loans		As at	Maximum Balance	As at	Maximum Balance
			31 March 2022	during the year	31 March 2021	during the year
	Unsecured, considered good					
	Loan to related parties (refer note 39.3)					
	-Alivira Animal Health Limited, Ireland		1,756.79	1,756.79	1,254.19	1,254.19
	Total		1,756.79	1,756.79	1,254.19	1,254.19

Notes:

i) The above loan are given for business purposes and also includes interest accrued upto 31.03.2022 Rs. 354.36 (31 March 2021: Rs. 311.73).

ii) The above disclosure is pursuant to Section 186 (4) of the Companies Act, 2013

iii) Details of loans and advances in the nature of loans granted to promoters, directors, key managerial personnel and related parties (as defined under Companies Act, 2013 is as below

Type of Borrower	As at 31 March 2022		As at 31 March 2021	
	Amount outstanding	% of Total	Amount outstanding	% of Total
a) Amount repayable on demand				
-Related Parties	1,756.79	100%	1,254.19	100%

8	Other non-current financial assets		As at	As at
			31 March 2022	31 March 2021
	Unsecured, considered good			
	Security deposits		16.46	21.78
	Margin money deposits		0.39	-
	Total		16.85	21.78

Note :Balance in margin money deposits are held as security against borrowings, guarantees and other commitments.

9	Deferred tax assets (net) (refer note 37)		As at	As at
			31 March 2022	31 March 2021
	Deferred tax liabilities			
	- Temporary differences on account of depreciation		(45.10)	(47.07)
	Total deferred tax liabilities (A)		(45.10)	(47.07)
	Deferred tax assets			
	- Expenses allowable on payment basis		26.62	27.17
	- Unabsorbed depreciation and carried forward of losses		-	28.49
	- Deferred tax assets on leased assets		-	24.07
	- MAT Credit Entitlement		119.61	125.05
	Total deferred tax assets (B)		146.23	180.71
	Total (B) - (A)		101.13	133.64

9.a	Income tax assets (net)		As at	As at
			31 March 2022	31 March 2021
	Advance income tax (net of provisions : Rs.161.27) (31 March 2021 : Rs. 125.45)		37.81	39.44
	Total		37.81	39.44



10	Other non-current assets	As at	As at
		31 March 2022	31 March 2021
	Unsecured, considered good		
	Capital advances	0.01	1.99
	Prepaid expenses	5.44	2.14
		<u>5.45</u>	<u>4.13</u>
11	Inventories	As at	As at
		31 March 2022	31 March 2021
	Raw materials and packing materials	183.25	95.85
	Goods-in transit	-	0.40
		<u>183.25</u>	<u>96.25</u>
	Work-in-progress and intermediates (refer note (i) below)		
	Finished goods	233.38	140.53
	Stock-in-trade	409.84	109.03
		<u>-</u>	<u>151.55</u>
		<u>409.84</u>	<u>260.58</u>
	Stock in transit	54.12	184.24
	Fuel	2.38	0.85
	Total Inventories (Lower of cost and net realisable value)	<u>882.97</u>	<u>682.45</u>

Notes:

(i) Details of inventory of work-in-progress and intermediates:

Bulk drugs	229.70	134.68
Formulations	3.68	5.85
Total	<u>233.38</u>	<u>140.53</u>

(ii) During the year ended 31 March 2022 Rs 0.93 (31 March 2021 : Rs. 19.7) net provision was recognised as an expense towards provision for slow moving, expired and near expiry inventories

12	Trade receivables	As at	As at
		31 March 2022	31 March 2021
	Unsecured, considered good	914.98	647.80
	Unsecured, considered good (related party)	149.03	189.31
	Trade receivables - Credit impaired	6.12	12.12
		<u>1,070.13</u>	<u>849.23</u>
	Impairment allowance (allowance for bad and doubtful debts)		
	Less: Allowance for doubtful trade receivables-Credit impaired	6.12	12.12
	Total	<u>1,064.01</u>	<u>837.11</u>

a. Trade Receivables ageing as on 31.03.2022

Particulars	Outstanding for following periods from due date of payment						Total
	Not due	Less than 6 months	6 months - 1 years	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade Receivables							
- considered good	806.51	247.31	8.15	0.25	1.79	-	1,064.01
- credit impaired	-	-	-	-	0.59	0.11	0.70
(ii) Disputed Trade Receivables							
- considered good	0	-	-	-	-	-	-
- credit impaired	-	-	1.30	0.00	3.60	0.52	5.42
Total	<u>806.51</u>	<u>247.31</u>	<u>9.45</u>	<u>0.25</u>	<u>5.98</u>	<u>0.63</u>	<u>1,070.13</u>

b. Trade Receivables ageing as on 31.03.2021

Particulars	Outstanding for following periods from due date of payment						Total
	Not due	Less than 6 months	6 months - 1 years	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade Receivables							
- considered good	622.75	197.04	10.20	4.92	-	0.02	834.93
- credit impaired	-	11.35	0.27	0.27	0.10	0.13	12.12
(ii) Disputed Trade Receivables							
- considered good	-	0.00	-	1.48	0.17	0.53	2.18
- credit impaired	0	-	-	-	-	-	-
Total	<u>622.75</u>	<u>208.39</u>	<u>10.47</u>	<u>6.67</u>	<u>0.27</u>	<u>0.68</u>	<u>849.23</u>

Notes:

1. No trade or other receivable are due from directors or other officers of the company either severally or jointly with any other person. Nor any trade or other receivable are due from firms or private companies respectively in which any director is a partner, a director or a member except as disclosed in Note 39.3 .
- 2.Refer note 47.3 for terms and other details



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

	As at 31 March 2022	As at 31 March 2021
13 Cash and cash equivalents		
Balances with banks		
- In current accounts	23.40	13.50
Cash on hand	0.07	0.04
Cheques on hand	2.62	-
Total	26.09	13.54
Cash and cash equivalents as defined in Ind AS 7 "Statements of Cash Flows"	26.09	13.54
14 Bank balances other than (note 13) above		
In earmarked accounts		
- Margin money deposits (refer note below)	16.37	21.17
Total	16.37	21.17
Note :Balance in margin money deposits are held as security against borrowings, guarantees and other commitments.		
15 Other current financial assets		
Unsecured, considered good		
Claims receivables	5.35	79.56
Foreign exchange forward contracts at FVTPL	2.76	0.62
Interest accrued on fixed deposits	0.26	0.52
Total	8.37	80.70
16 Other current assets		
Unsecured, considered good		
Advance to suppliers	13.51	1.66
Balances with government authorities	154.77	99.16
Prepaid expenses	4.67	9.61
Others	1.56	2.35
Total	174.51	112.79



	As at 31 March 2022		As at 31 March 2021	
	No. of Shares	Rs.	No. of Shares	Rs.
17 Equity Share capital				
(a) Authorised				
Equity shares of Rs.10 each	15,80,00,000	1,580.00	15,80,00,000	1,580.00
(b) Issued, subscribed and fully paid-up				
Equity shares of Rs.10 each	4,77,76,470	477.76	4,77,76,470	477.76
Total		477.76		477.76

Notes:

(i) Reconciliation of the number of shares and amount outstanding

Fully paid equity shares

Balance as on 1 April 2020
Share issued during the year
Balance as on 31 March 2021

	No. of Shares	Share capital
Balance as on 1 April 2020	4,77,76,470	477.76
Share issued during the year	-	-
Balance as on 31 March 2021	4,77,76,470	477.76
Share issued during the year	-	-
Balance as on 31 March 2022	4,77,76,470	477.76

(ii) Terms / rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs.10 per share. Each holder of equity shares is entitled to one vote per share. Each equity shareholder is entitled to dividend in the Company. The dividend proposed by Board of directors is subject to approval of the shareholders in the ensuing annual general meeting. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.

(iii) Details of shares held by holding company

Name of the shareholder & promoter	As at 31 March 2022		As at 31 March 2021	
	No. of shares held	% of holding	No. of shares held	% of holding
SeQuent Scientific Limited and its nominees	4,77,76,470	100%	4,77,76,470	100%

(iv) Details of shares held by each shareholder holding more than 5% shares

Equity shares

Name of the shareholder	As at 31 March 2022		As at 31 March 2021	
	No. of shares held	% of holding	No. of shares held	% of holding
SeQuent Scientific Limited and its nominees	4,77,76,470	100%	4,77,76,470	100%



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

	As at 31 March 2022	As at 31 March 2021
18 Other equity		
Retained earnings	238.04	98.65
Securities premium	4,230.73	4,230.73
Share options outstanding account	182.27	60.59
Other reserves	45.10	31.79
General reserve	54.24	52.73
Total	4,750.38	4,474.49
(a) Retained earnings		
	As at 31 March 2022	As at 31 March 2021
Balance at the beginning of the year	98.65	(200.25)
Add: Profit during the year	139.46	298.04
Add: Other comprehensive income	2.46	2.26
Less: Fair value gain on Corporate guarantee	(2.53)	(1.40)
Balance at the end of the year	238.04	98.65
(b) Securities premium account		
	As at 31 March 2022	As at 31 March 2021
Balance at the beginning of the year	4,230.73	4,230.73
Balance at the end of the year	4,230.73	4,230.73
(c) Share options outstanding account		
	As at 31 March 2022	As at 31 March 2021
Balance at the beginning of the year	60.59	60.59
Add: Employee stock option expenses	123.19	0.71
Less: Transferred to general reserve on vested ESOP lapsed during the year	(1.51)	(0.71)
Balance at the end of the year	182.27	60.59
(d) Other reserves		
	As at 31 March 2022	As at 31 March 2021
Balance at the beginning of the year	31.79	26.70
Add: Movement during the year	13.31	5.09
Balance at the end of the year	45.10	31.79
(e) General reserve		
	As at 31 March 2022	As at 31 March 2021
Balance at the beginning of the year	52.73	52.02
Add: Vested ESOP lapsed during the year	1.51	0.71
Balance at the end of the year	54.24	52.73

Nature and purpose of Reserves

(a) Retained earnings

Retained earnings are the profits that the Company has earned till the date, less any transfers to general reserve and dividends or other distributions paid to shareholders.

(b) Securities premium account

Securities premium includes the difference between the face value of the equity shares and the consideration received in respect of shares issued.

(c) Share options outstanding account

This relate to shares of the Parent Company, granted by the Parent Company to specific employees of the Company under its employee share based payment arrangement.

(d) Other reserves

The Company has availed certain loans from financial institutions / banks which have been guaranteed by SeQuent Scientific Limited, the Parent Company, at no consideration. Other reserves represents fair value of these services availed from the Parent Company.

(e) General reserve

General reserve represents vested ESOP lapsed on resignation of the employee the Company.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

19 Non-current borrowings	As at 31 March 2022	As at 31 March 2021
Secured term loans - at amortised cost		
From other parties	-	0.51
Unsecured term loan - at amortised cost		
From related parties	2,428.87	2,207.30
Total	2,428.87	2,207.81

(i) Details of terms of repayment for the long-term borrowings and security provided in respect of the secured long-term borrowings:

Particulars	As at 31 March 2022	As at 31 March 2021
Term loan from parties:		
Toyota Financial Services India Limited: Hypothecation of asset (vehicle). Repayable in 60 equal monthly Instalments, commencing from October 2017, now fully repaid	-	0.19
Toyota Financial Services India Limited: Hypothecation of asset (vehicle). Repayable in 60 equal monthly Instalments, commencing from January 2018, now fully repaid	-	0.32
Total	-	0.51

(i) For the current maturities of long-term borrowings, refer note 23.

(ii) The interest on loan from related parties are floating in nature which ranges from 7.5% p.a. to 7.8% p.a. (31 March 2021: 7.8%to 9.9% p.a.)

20 Other non current Financial liabilities	As at 31 March 2022	As at 31 March 2021
Lease liabilities (Refer Note 48)	101.42	119.06
Total	101.42	119.06

21 Non-current provisions	As at 31 March 2022	As at 31 March 2021
Provision for employee benefits		
Gratuity (refer note 41)	26.02	31.03
Compensated absences (refer note below)	18.90	11.34
Other	4.97	-
Total	49.89	42.37

Note:

The provision for compensated absences includes annual leave and vested long service leave entitlement accrued.

22 Other non-current liabilities	As at 31 March 2022	As at 31 March 2021
Corporate guarantee liability	1.27	0.63
Total	1.27	0.63

23 Current borrowings	As at 31 March 2022	As at 31 March 2021
Loans repayable on demand		
Secured loan - at amortised cost		
From banks (refer note (i) & (ii) below)	738.04	380.96
Current maturities of long-term borrowings (refer note (iii) below)	-	0.77
Total	738.04	381.73

Notes:

- (i) Working capital loan from banks are secured by a first pari-passu charge on current assets of the Company, both present and future, and unconditional irrevocable corporate guarantee of SeQuent Scientific Limited - holding company, shortfall undertaking from SeQuent Scientific Limited
- (ii) The interest rate on Working Capital loans are floating in nature which ranges from 4.8% p.a. to 5.75% p.a. (31 March 2021: 5.75%to 9.45% p.a.)
- (iii) The details of interest rates, repayment terms, securities, guarantees and others terms are disclosed under note 19. Details of current maturities of long-term debt are as below:

Secured term loan from other parties	As at 31 March 2022	As at 31 March 2021
Toyota Financial Services India Limited	-	0.77
Total	-	0.77



24 Trade payables

	As at 31 March 2022	As at 31 March 2021
Micro and small enterprises (refer note 43)	57.87	38.97
Others	409.30	406.79
Related parties (Refer Note 39.3)	295.53	268.14
Total	762.70	713.90

a. Trade payable ageing as on 31.03.2022

Particulars	Outstanding for following periods from due date of payment						Total
	Unbilled	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade Payables							
-Micro enterprises and small enterprises	8.59	43.42	3.81	-	-	-	55.82
-Others	102.50	568.73	32.10	0.49	0.90	0.11	704.83
Disputed Trade Payables							
-Micro enterprises and small enterprises	-	-	0.20	1.85	-	-	2.05
-Others	-	-	-	-	-	-	-
Total	111.09	612.15	36.11	2.34	0.90	0.11	762.70

b. Trade payable ageing as on 31.03.2021

Particulars	Outstanding for following periods from due date of payment						Total
	Unbilled	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade Payables							
-Micro enterprises and small enterprises	10.70	18.65	9.62				38.97
-Others	98.99	382.72	188.84	2.33	-	-	672.88
Disputed Trade Payables							
-Micro enterprises and small enterprises			2.05				-
-Others							2.05
Total	109.69	401.37	200.51	2.33	-	-	713.90

Notes:

- (i) Trade payables (other than due to micro and small enterprises) are non-interest bearing and are normally settled in 90 - 120 days.
(ii) The Company's exposures to currency and liquidity risks related to trade payables is disclosed in note 47.

25 Other current financial liabilities

	As at 31 March 2022	As at 31 March 2021
Interest accrued and due on borrowings	3.26	1.09
Payables on purchase of property, plant and equipments	12.15	16.57
Others	7.28	0.50
Total	22.69	18.16

26 Current lease liabilities

	As at 31 March 2022	As at 31 March 2021
Lease liabilities (Refer Note 48)	4.15	4.09
Total	4.15	4.09

27 Current provisions

	As at 31 March 2022	As at 31 March 2021
Provision for employee benefits		
Gratuity (refer note 41)	6.14	4.04
Compensated absences	7.48	14.96
Other	6.09	9.15
Total	19.71	28.15

28 Other current liabilities

	As at 31 March 2022	As at 31 March 2021
Statutory remittances	22.66	19.96
Advances from customers	8.61	26.47
Total	31.27	46.43



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

29 Revenue from operations

	Year ended 31 March 2022	Year ended 31 March 2021
Sale of products	4,714.70	4,062.75
Sale of Services	54.46	112.83
Other operating revenues		
Sale of scrap	3.74	2.49
Sale of Import licences	-	23.89
Duty drawback and other export incentives	11.98	31.64
Total	4,784.88	4,233.60
Notes		
(i) Sale of product comprises		
(a) Manufacturing goods		
Bulk drugs	2,108.78	1,728.95
Formulations	150.79	154.96
Total - Sale of manufactured products	2,259.57	1,883.91
(b) Traded goods		
Bulk drugs	1,400.61	1,385.04
Formulations	1,054.52	793.80
Total - Sale of traded goods	2,455.13	2,178.84
Total - Sale of products	4,714.70	4,062.75

Disaggregated revenue disclosure

The company disaggregate the revenue based on geographic locations and it is disclosed under note 40 Segment Reporting.

Trade receivables and contract balances

The company classifies the right to consideration in exchange for deliverables as a trade receivable.

A receivable is the right to consideration that is upon passage of time. Revenue for contracts with customers are recognized at a point in time when the company transfers control over the product to the customers.

Reconciliation of revenue from sale of products and services with the contracted price

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
Contracted price	4,810.44	4,256.84
Less: trade discounts and returns	41.28	81.26
Sale of products and services	4,769.16	4,175.58

30 Other income

	Year ended 31 March 2022	Year ended 31 March 2021
Interest income (refer note (i) below)	32.32	17.65
Net gain on foreign currency transactions and translation	68.39	-
Gain on sale of property, plant and equipment's	0.17	0.14
Corporate guarantee commission	6.79	2.81
Gain on sale of investments	-	5.23
Profit on termination of Lease	3.89	-
Corporate Cross Charge	48.31	98.10
Provision for trade receivables written back	4.81	0.80
Miscellaneous income	8.20	2.31
Total	172.89	127.04
(i) Interest income comprises:		
Interest on:		
Bank deposits	0.68	3.41
Loans to related parties	30.86	14.24
Other	0.78	-
Total	32.32	17.65



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

31.a Cost of materials consumed

	Year ended 31 March 2022	Year ended 31 March 2021
Opening stock	96.25	89.36
Add: Purchases	1,449.64	1,108.17
Less: Closing stock	183.25	96.25
Total	1,362.64	1,101.28
Materials consumed comprises:		
Solvents	167.91	82.00
Chemicals	1,194.73	1,019.28
Total	1,362.64	1,101.28

31.b Purchases of stock-in-trade

	Year ended 31 March 2022	Year ended 31 March 2021
Purchases of stock-in-trade	1,529.28	1,467.95
Total	1,529.28	1,467.95
Purchases of stock-in-trade comprises:		
Bulk drugs	908.39	981.02
Formulations	620.89	486.93
Total	1,529.28	1,467.95

31.c Changes in inventories of finished goods, stock-in-trade and work-in-progress

	Year ended 31 March 2022	Year ended 31 March 2021
Opening stock		
Work-in-progress and intermediates	140.53	207.84
Finished goods (including stock-in-trade)	444.82	162.64
	585.35	370.48
Closing stock		
Work-in-progress and intermediates	233.38	140.53
Finished goods (including stock-in-trade)	463.96	444.82
	697.34	585.35
Net increase	(111.99)	(214.87)

32 Employee benefits expense

	Year ended 31 March 2022	Year ended 31 March 2021
Salaries and wages	471.68	426.24
Contributions to provident fund, gratuity and other funds (refer note 41)	37.02	32.66
Share-based payments to employees (refer note 46)	153.15	36.68
Staff welfare expenses	20.17	12.61
Total	682.02	508.19

33 Finance costs

	Year ended 31 March 2022	Year ended 31 March 2021
Interest expense on borrowings	202.28	195.12
Other borrowing costs	13.66	38.34
Interest expense on leases liabilities (Refer note 48)	11.95	12.63
Total	227.89	246.09

34 Depreciation and amortisation expense

	Year ended 31 March 2022	Year ended 31 March 2021
Depreciation on tangible assets	182.29	144.48
Depreciation on right-of-use assets	12.45	12.73
Amortization of intangible assets	8.37	46.90
Total	203.11	204.11



Allivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

35 Other expenses

	Year ended 31 March 2022	Year ended 31 March 2021
Travelling and conveyance	31.30	17.76
Communication expenses	4.45	5.96
Consumables	119.29	77.50
Conversion and processing charges	86.93	47.00
Contract labour charges	9.01	10.41
Legal and professional charges	68.73	90.14
Freight and forwarding	141.74	115.03
Power, water and fuel	123.24	95.58
Rent	2.20	0.29
Analytical charges	66.63	57.91
Repairs and maintenance		
Buildings	7.79	6.05
Machinery	29.70	26.19
Others	13.79	43.75
Insurance	14.51	10.65
Commission on sales	36.87	43.73
Advertisement and selling expenses	34.53	20.64
Rates and taxes	5.09	11.68
Bad loans and advances written off	0.99	-
Payments to auditors (refer note (i) below)	7.53	4.42
Bad trade receivables written off	1.07	-
Allowance doubtful trade receivable	(0.64)	-
Net loss on foreign currency transactions and translation	-	10.10
Miscellaneous expense	53.63	37.43
Total	858.38	732.22

Note:

(i) Payments to the auditors comprises (net of Goods and Services Tax credit):

As auditors - statutory audit	6.60	1.70
Fees for certifications and other services	0.91	2.65
Reimbursement of expenses	0.02	0.07
Total	7.53	4.42

36 Exceptional items*

	Year ended 31 March 2022	Year ended 31 March 2021
Accelerated ESOP costs	-	18.13
One time bonus	-	6.22
Total	-	24.35

*Refer note 46E



37 Reconciliations of tax expenses and details of deferred tax balances
A) Income tax expense recognised in the statement of profit and loss

	Year ended 31 March 2022	Year ended 31 March 2021
i) Income tax expense recognised in the statement of profit and loss		
Current tax	35.82	47.99
Total (I)	<u>35.82</u>	<u>47.99</u>
Deferred Tax charge		
Origination and reversal of temporary differences	25.72	(6.70)
Total (II)	<u>25.72</u>	<u>(6.70)</u>
MAT		
MAT credit entitlement	5.44	(44.55)
Total (III)	<u>5.44</u>	<u>(44.55)</u>
Provision for tax of earlier years written back (IV)	-	(3.46)
Total (V = I+II+III+IV)	<u>66.98</u>	<u>(6.72)</u>
ii) Tax on other comprehensive income		
Re-measurement (gains) / losses on defined benefit plans	1.33	1.21
Total (VI)	<u>1.33</u>	<u>1.21</u>
Total (V+VI)	<u>68.31</u>	<u>(5.51)</u>

B) Reconciliation of effective tax rate

The reconciliation between the statutory income tax rate applicable to the Company and the effective income tax rate of the Company is as follows:

	Year ended 31 March 2022	Year ended 31 March 2021
Profit before tax	206.44	291.32
Statutory income tax rate	34.94%	34.94%
Tax as per applicable tax rate	<u>72.14</u>	<u>101.80</u>
Differences due to:		
- Effect of additional allowance net of MAT credit	(5.44)	(103.02)
- Provision for tax of earlier years written back	-	(3.46)
- Others	0.28	(2.04)
Income tax expenses charged to the statement of profit and loss	<u>66.98</u>	<u>(6.72)</u>
Effective tax rate	<u>32.44%</u>	<u>-2.31%</u>

During the year the Company has recognised MAT credit/(charge) entitlement which is expected to be available for set off in the future years.

C) Movement in deferred tax assets and liabilities

	As at 1 April 2021	Credit / (charge) in the statement of profit and loss	Credit / (charge) in other comprehensive income	As at 31 March 2022
Deferred tax asset (Net)				
- Temporary differences on account of depreciation	(47.07)	1.97	-	(45.10)
- Expenses allowable on payment basis	27.17	0.80	(1.33)	26.62
- Unabsorbed depreciation and carried forward of losses	28.49	(28.49)	-	-
- MAT credit entitlement	125.05	(5.44)	-	119.61
Total	<u>133.64</u>	<u>(31.16)</u>	<u>(1.33)</u>	<u>101.13</u>
	As at 1 April 2020	Credit / (charge) in the statement of profit and loss	Credit in other comprehensive income	As at 31 March 2021
Deferred tax asset (Net)				
- Temporary differences on account of depreciation	(32.78)	(14.29)	-	(47.07)
- Expenses allowable on payment basis	35.88	(7.50)	(1.21)	27.17
- Unabsorbed depreciation and carried forward of losses	-	28.49	-	28.49
- MAT credit entitlement	80.50	44.55	-	125.05
Total	<u>83.60</u>	<u>51.25</u>	<u>(1.21)</u>	<u>133.64</u>

D) The Company has not opted for section 115BAA introduced under Taxation Law (Amendment) Ordinance, 2019, considering the accumulated MAT credit, tax losses and other benefits available under the Income Tax Act, 1961.



38 Earnings per share

Profit attributable to equity shareholders

Profit for the year attributable to equity holders of the Company

Profit attributable to equity shareholders for basic and diluted earnings

	Year ended 31 March 2022	Year ended 31 March 2021
	139.46	298.04
	<u>139.46</u>	<u>298.04</u>

Weighted average number of equity shares

Equity shares at beginning of the year

Effect of shares issued during the year

Weighted average number of equity shares at end of the year for basic and diluted EPS

	Year ended 31 March 2022	Year ended 31 March 2021
	4,77,76,470	4,77,76,470
	-	-
	<u>4,77,76,470</u>	<u>4,77,76,470</u>

Basic earnings per share(in Rs.)

Diluted earnings per share(in Rs.)

	Year ended 31 March 2022	Year ended 31 March 2021
	2.92	6.24
	2.92	6.24



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

39 Related party transactions

39.1 List of related parties

(I) Related parties where control exists

a) Ultimate Holding Company
CA Harbor Investments

b) Holding Company
SeQuent Scientific Limited

c) Subsidiaries

Wholly-owned subsidiary:
Alivira Animal Health Limited, Ireland

Step down subsidiaries:
Alivira Animal Health Australia Pty Limited (Strike off w.e.f. May 13, 2020)
Provet Veteriner Ürünleri San. Ve Tic. A. Ş.
Topkim Topkapi İlaç premiks Sanayi Ve Ticaret A.Ş.
Fendigo SA
Fendigo BV
N-Vet AB
Alivira Saude Animal Brasil Participacoes Ltda
Alivira Saude Animal Ltda. (Name changed from Interchange Veterinária Indústria E Comércio Ltda w.e.f 20 January 2022)
Laboratorios Karizoo, S.A.
Laboratorios Karizoo, S.A. DE C.V. (Mexico)
Comercial Vila Veterinaria De Lleida S.L.
Phytotherapeutic Solutions S.L
Vila Viña Participacions S.L.
Alivira France
Bremer Pharma GmbH
Evanvet Distribuidora De Produtos Veterinarios Ltda (Name changed from 'Evince Saude Animal Ltda w.e.f 03 February 2021)
Alivira Italia S.R.L.
Alivira Animal Health USA LLC
Alivira Animal Health UK Ltd
Nourri Sae nutria Animal (Nourrie) (Refer Note (ii))

(II) Other related parties with whom transactions have taken place during the year

(a) Key management personnel

Mr. Manish Gupta, Chief Executive Officer & Managing Director (resigned w.e.f 10 April 2022)
Mr. Rajaram Narayan, Chief Executive Officer & Managing Director (appointed w.e.f 11 April 2022)
Mr. Sharat Narasapur, Joint Managing Director
Mr. Tushar Mistry, Chief Financial Officer
Dr. Kamal Sharma, Independent Director (appointed w.e.f September 2020)
Mr. Rahul Mukim, Non-Executive Director (appointed w.e.f September 2020)
Mrs. Kalpana Mukherjee, Whole-Time Director (resigned w.e.f November 22, 2021)
Ms. Vijayalakshmi Vaithianathan, Non- Executive Director (appointed w.e.f 15, December 2021)
Mr. Lokesh Kumar (Exim Bank Nominee) (resigned w.e.f 14 January 2021)
Dr. Gopakumar Nair (resigned w.e.f 9 September 2020)

b) Fellow subsidiaries:
SeQuent Research Limited

c) Enterprises owned or significantly influenced by individuals who have control / significant influence over the Company
Solara Active Pharma Sciences Limited (till 17th August 2020)

Note:


- i) All the transactions entered with related parties are in the ordinary course of business and on arm's length basis
ii) Alivira Saude Animal Ltda has acquired 100% stake in Nourrie on 28th February 2022.

Above mentioned provides the information about the Company's structure including the details of the subsidiaries and the holding company. The following table provides transactions that have been entered into with related parties for the relevant financial year:



Transactions for the year


	Holding Company		Wholly-owned subsidiary		Step down subsidiaries		Fellow subsidiaries		Enterprises owned or significantly influenced by individuals who have control / significant influence over the Company		Key management personnel and their relatives	
	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021
Mrs Kalpana Mukherjee Short-term benefits Share based payments											1.99	2.84
Director sitting fees Dr. Gopal Kumar Nair Dr. Kamal K. Sharma Lokesh Kumar (Exim. Bank Nominee)											1.99	3.83
Analytical charges SeQuent Research Limited								48.24			-	6.67
Payment towards lease obligation and finance costs (previous year - rent expenses) SeQuent Scientific Limited	9.26	8.82										
Guarantee commission income Alivra Animal Health Limited, Ireland SeQuent Scientific Limited	1.90	1.97	3.29	0.85								
Bremer Pharma GmbH Alivra Saude Guarantee commission expenses SeQuent Scientific Limited	10.21	9.37			0.31 1.33							0.20 0.30 0.40
Additional guarantee received the year SeQuent Scientific Limited	423.49	278.53										
Additional / (reduction) of guarantee given during the year (net) SeQuent Scientific Limited Alivra Saude Brazil Bremer Pharma GmbH Alivra Animal Health Limited, Ireland	-	(103.41)	(19.66)	730.80	627.09 84.03	103.93 37.88						
Employee Stock Option expenses SeQuent Scientific Limited	150.53	36.68										
Corporate Cross Charge Income SeQuent Scientific Limited Alivra Animal Health Limited, Ireland SeQuent Research Limited	27.00	73.30	12.50	14.15			8.81					10.64
Cross Charge Expense SeQuent Scientific Limited	25.88	39.67										
Loans given by the Company Alivra Animal Health Limited, Ireland			426.62	933.15								
Borrowings SeQuent Scientific Limited Investment (Increase due to ESOP cost) Alivra Animal Health Limited, Ireland	20.00	1,534.50	119.37	10.14								



39 Related party transactions

39.3 Balance as at balance sheet date

	Holding Company		Wholly-owned subsidiary		Step down subsidiaries		Fellow subsidiaries		Enterprises owned or significantly influenced by individuals who have control/ significant influence over the Company		Key management personnel and their relatives	
	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021	Year ended 31 March 2022	Year ended 31 March 2021
(i) Trade receivables Alivira Animal Health Limited, Ireland Laboratorios Kaizoo, S.A. Bremer Pharma GmbH Alivira Saude Animal Ltda Topkiri Topkiri Isp. Premiks Sansyl Ve Ticaret A.Ş. Alivira Saude			131.76	182.98	- 1.64 - 9.38 6.25	0.04 6.14 0.15 - -						
(ii) Loan receivable Alivira Animal Health Limited, Ireland			1,756.79	1,254.19								
(iii) Borrowings SeQuent Scientific Limited SeQuent Research Limited	2,384.96	2,207.30					43.81	-				
(iv) Trade Payables SeQuent Scientific Limited SeQuent Research Limited Laboratorios Kaizoo, S.A. Bremer Pharma GmbH Solira Active Pharma Sciences Limited Alivira Animal Health Limited, Ireland	290.59	283.15	1.13	1.25	0.77	0.03 0.63	3.04	3.08	-	35.92		
(v) Corporate guarantee received from SeQuent Scientific Limited	2,451.72	2,028.23										
(vi) Corporate guarantee given to Alivira Animal Health Limited, Ireland Alivira Animal Saude Brazil Bremer Pharma SeQuent Scientific Limited			711.14	730.80	731.01 121.91	103.93 37.88						
	380.00	380.00										



40 Segment Reporting

Operating segment are reported in a manner consistent with the Internal reporting provided to the Chief Operating Decision Maker (CODM) of the Company. The CODM who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Executive Management Committee of the Company. The Company is mainly engaged in the business of veterinary healthcare which as per Ind AS 108 - "Operating segments" is considered the only business segment and all other activities of the Company are incidental to this business segment.

The Company operates in three principal geographic locations.

- (i) Europe
- (ii) Asia
- (iii) Rest of the world

	Year ended 31 March , 2022	Year ended 31 March , 2021
I. Revenue from operations		
Europe	1,628.72	1,557.06
Asia	1,501.45	1,444.73
Rest of the world	1,654.71	1,231.81
Total	4,784.88	4,233.60
	As at 31 Mach 2022	As at 31 Mach 2021
II. Total assets		
Europe	413.06	444.41
Asia	2,918.73	2,816.88
Rest of the world	478.63	263.39
Total segment assets	3,810.42	3,524.68
Unallocable (*)	5,577.73	4,989.88
Total assets	9,388.15	8,514.56
III. Cost incurred during the year to acquire segment assets		
Europe	-	-
Asia	77.76	256.42
Rest of the world	-	-
Total	77.76	256.42

Information about major customer, refer note 47.3

Note: In presenting geographic information, segment revenue has been based on the selling location in relation to sales to customers and segment assets are based on geographical location of assets.

(*) Unallocable assets comprises of investments in subsidiary, loans and deferred tax assets (net) .



41 Employee benefit plans

(i) Defined contribution plans:

The Company makes Provident Fund and Employee State Insurance Scheme contributions which are defined contribution plans, for qualifying employees. Under the Schemes, the Company is required to contribute a specified percentage of the payroll costs to fund the benefits. The Company recognised Rs 27.17 (31 March 2021 : Rs.24.04) for Provident Fund contributions and Rs.1.89 (31 March 2021 : Rs. 1.43) for Employee State Insurance Scheme contributions in the statement of profit and loss. As at 31 March 2022, contribution of Rs.4.77 (31 March 2021 : Rs.4.36) is outstanding which is paid subsequent to the end of respective reporting periods.

(ii) Defined benefit plan:

The Company has a defined gratuity benefit plan. Gratuity is payable to all eligible employees of the Company on superannuation, death and resignation. The following table summarizes the components of net employee benefit expenses recognised in the statement of profit and loss and the funded status and amounts recognised in the balance sheet for the plan.

	31 March 2022	31 March 2021
Expense / (income) recognised in the statement of profit and loss:		
Current service cost	7.95	7.19
Net Interest cost	2.18	1.99
Expected return on plan assets	(0.01)	(0.02)
Component of defined benefit costs recognised in the statement of profit and loss	10.12	9.16
Expense / (income) recognised in other comprehensive		
Return on plan assets (excluding amounts included in net interest cost)	-	-
Actuarial (gains) / losses arising from changes in financial assumptions	(2.48)	(0.14)
Actuarial (gains) / losses arising from changes in experience adjustments	(1.50)	(3.40)
Actuarial (gains) / losses arising from adjustment to opening fairvalue	0.19	0.07
Component of defined benefit costs recognised in other comprehensive income	(3.79)	(3.47)
Total	6.33	5.67

Net defined benefit obligation as reflected in Balance Sheet.

	31 March 2022	31 March 2021
Present value of defined benefit obligation (DBO)	32.16	35.25
Fair value of plan assets	(0.00)	(0.18)
Net liability recognised in balance sheet	32.16	35.07

A. Movements in the present value of the defined benefit obligation are as follows.

	31 March 2022	31 March 2021
Opening defined benefit obligation	35.25	32.08
Current service cost	7.95	7.19
Interest cost	2.18	1.99
Benefits paid	(7.16)	(2.47)
Acquisition / Divestiture	(2.08)	
Actuarial loss (gain) arising from:		
Actuarial gains and losses arising from changes in financial assumptions	(2.48)	(0.14)
Actuarial gains and losses arising from changes in experience adjustments	(1.50)	(3.40)
Closing defined benefit obligation	32.16	35.25

B. Movements in the fair value of plan assets are as follows.

	31 March 2022	31 March 2021
Opening fair value of plan assets	0.18	0.24
Opening fair value adjustment	-	(0.08)
Expected return on plan assets	0.01	0.02
Remeasurement loss (gain):		
Return on plan assets (excluding amounts included in net interest cost)	(0.19)	-
Closing fair value of plan assets	0.00	0.18



Alivira Animal Health Limited

Notes to the financial statements for the year ended 31 March 2022

All amounts are in Rs. million unless otherwise stated

Actuarial assumptions

The principal assumptions used for the purpose of actuarial valuations are shown in the table below. The assumptions as at the balance sheet date are used to determine the present value of defined benefit obligation at that date.

	<u>31 March 2022</u>	<u>31 March 2021</u>
Financial assumption:		
Discount rate	6.89%	6.58%
Salary escalation rate	7.00%	8.00%
Demographic assumption:		
Withdrawal rate	12.00%	12.00%
Mortality rate	IALM (2012-14) Ultimate	IALM (2012-14) Ultimate
Retirement Age	58 yrs.	58 yrs.

As per para 83 of Ind AS 19, the rate used to discount post-employment benefit obligation (both funded and unfunded) shall be determined by reference to market yields at the end of the reporting period on government bonds.

	<u>31 March 2022</u>	<u>31 March 2021</u>
Expected future cash flows		
Within 1 Year	6.14	4.22
2-5 years	14.55	16.98
6-10 years	12.01	14.42
Average expected future working life is 7.7 years (previous year 7.74 years)		

Sensitivity Analysis

The sensitivity analyses below have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period. The sensitivity analyses are based on a change in a significant assumption, keeping all other assumptions constant. The sensitivity analyses may not be representative of an actual change in the defined benefit obligation as it is unlikely that changes in assumptions would occur in isolation from one another.

	<u>Impact on the defined benefit obligation</u>	
	<u>100 bps increase</u>	<u>100 bps decrease</u>
31 March 2022		
Discounting rate	(1.68)	1.87
Salary escalation rate	1.85	(1.71)
31 March 2021		
Discounting rate	(2.06)	2.31
Salary escalation rate	2.24	(2.05)



42 Contingent liabilities and commitments (to the extent not provided for)

Contingent liabilities

	As at 31 March 2022	As at 31 March 2021
Ramky Escalation charges	16.66	16.66

The Company has a manufacturing plant at Vizag, Andhra Pradesh wherein effluent treatment services are provided by Ramky Pharmacy India Private Limited (Lessor for the lease hold property). The lessor has raised escalated demand of Rs. 49.56 towards Infrastructure development cost out of which an interim demand of Rs. 32.90 has been paid and charged to the statement of Profit & Loss, in the earlier years. The balance amount of Rs. 16.60 is under discussion by lessor with Andhra Pradesh Industrial Infrastructure Corporation and has been disclosed as contingent liability in the financial statements.

	As at 31 March 2022	As at 31 March 2021
Commitments		
a. Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)		
- Property, plant and equipment	123.20	5.60
- Corporate Guarantee given to lenders for loan facility availed by wholly owned subsidiary	711.14	730.80
- Corporate Guarantee given to lenders for loan facility availed by step down subsidiary	852.92	141.81
- Corporate Guarantee given to lenders for loan facility availed by holding company	380.00	380.00

b. The Company has given a letter of support to its wholly owned subsidiary Alivira Animal Health Limited, Ireland to continue to assist in whatever manner that it can to financially support the operations and cash flow requirements of the subsidiary for the foreseeable future.

43 Dues to micro and small enterprises (refer note 25)

	As at 31 March 2022	As at 31 March 2021
The amounts remaining unpaid to micro and small suppliers as at the end of the year	57.87	38.97
Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	0.48	0.24
The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day	-	-
The amount of interest due and payable for the year	1.41	0.86
The amount of interest accrued and remaining unpaid at the end of the accounting year	2.27	0.86
The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above are actually paid	-	-

Dues to micro and small enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management based on enquiries made by the Management with the creditors.

44 Corporate Social Responsibility Expenses (CSR)

The Company has incurred below expenses towards CSR activities as per section 135 of the Companies Act, 2013 and is included in other expenses:

Details of CSR spent during the financial year:

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
(i) Amount required to be spent by the company during the year,	2.82	1.68
(ii) Amount of expenditure incurred,	1.80	0.03
(iii) Shortfall at the end of the year*	1.02	1.65
(iv) Total of previous years shortfall*	1.65	-
(v) Total CSR Expenditure	2.82	1.68
Nature of CSR activities		
PM Cares Funds		0.03
Chirag Rural Development Foundation	1.09	
Dev Loka Educational Trust	0.71	
Total	1.80	0.03
Utilization of Unspent CSR of FY 20-21		
Chirag Rural Development Foundation	0.62	
Dev Loka Educational Trust	1.04	
Total	1.66	-

* Amount is transferred to unspent CSR account



45 Details of research and development (R&D) expenditure

	31 March 2022			31 March 2021		
	Ambarnath Formulations	Vizag API	Total	Ambarnath Formulations	Vizag API	Total
Revenue expenditure						
Employee benefit expenses	20.10	35.57	55.67	14.59	33.35	47.94
Legal and professional fees	2.44	0.04	2.48	1.37	-	1.37
Raw materials and consumables	7.86	7.54	15.40	7.29	3.17	10.46
Travelling and conveyance	0.06	0.11	0.17	0.06	0.16	0.22
Analytical charges	1.91	37.60	39.51	2.02	34.34	36.36
Depreciation	6.50	3.43	9.93	5.00	19.47	24.47
Repairs & maintenance	1.02	0.53	1.55	1.07	0.63	1.70
Others	4.69	3.44	8.13	3.45	5.55	9.02
Total	44.58	88.26	132.84	34.85	96.63	131.54
Capital expenditure						
Purchase of Property, plant and equipment (including pilot plant)	13.74	-	13.74	13.52	0.65	14.16
Total	13.74	-	13.74	13.52	0.65	14.16

Notes:

- 1 Vizag R&D unit got approved by Department of Scientific and Industrial Research (Certificate no-F. No. TU/IV-RD/4453/2019)
- 2 For Ambarnath formulation R&D unit Department of Scientific and Industrial Research application is yet to be made.



46. Share-based payment arrangements:

A. Employees Stock Option Plan:

Pursuant to the Employees Stock Options plan established by the holding company (i.e. Sequent Scientific Limited), stock options were granted to the employees of the Company.

Grant Date	No. of Options	Vesting conditions	Contractual life of the options vesting Period
11 January 2016 (*)	3,50,000	The options granted would normally vest over a maximum period of 4 years from the date of the grant in proportions specified in 'SeQuent ESOP 2010' scheme.	5 years
14 May 2016	1,25,000		
23 May 2017	50,000		
02 November 2018	23,25,000		
03 July 2019	5,00,000		
21 September 2020	70,900	The options granted would vest over a maximum period of 1 years from the date of the grant	1 year
01 March 2021	34,50,000	The options granted would normally vest over a maximum period of 5 years from the date of the grant in proportions specified in 'SeQuent ESOP 2020' scheme.	6 Years

* Pursuant to sub-division of 1 equity share of Rs.10 each into 5 equity shares of Rs 2 each on 26 February 2016, the no. of options have been adjusted proportionately.

The expense on Employee Stock Option plan debited to the statement of profit and loss during 2021-22 is Rs.153.15. The entire amount pertains to equity-settled employee share-based payment plans.

The Company has revised the estimate, based on legal advice, in respect of number of Employees Stock Options Plan (ESOP) expected to vest under ESOP Scheme 2020, consequent to resignation of the Managing Director and Chief Financial Officer during the current financial year. Accordingly, the Company has reversed the employee benefit expense amounting to Rs.6.78 million during the current financial year.

B. Reconciliation of outstanding share options

The number and weighted-average exercise prices of share options under the share option programmes were as follows:

	March 31, 2022		March 31, 2021	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Employees Stock Option Plan:				
Option outstanding at the beginning of the year	36,24,800	84.77	20,09,750	40.00
Granted during the year	-	-	35,20,900	85.07
Exercised during the year	7,14,200	78.16	16,89,750	40.00
Forfeited during the year	18,58,100	85.80	2,16,100	44.57
Options outstanding at the end of the year	10,52,500	84.03	36,24,800	84.77

C. Share options exercised during the year

The following share options were exercised during the year:

Option series	Number exercised	Exercise date	Share price at exercise date
1. Granted on 21 September 2021	27,300	26-Oct-21	180.70
2. Granted on 21 September 2021	8,800	01-Dec-21	153.18
3. Granted on 21 September 2021	20,600	24-Feb-22	129.83
5. Granted on 03 Nov 2018	65,000	08-Mar-22	122.85
4. Granted on 01 March 2021	5,92,500	08-Mar-22	122.85

D. Share options exercised at the end of the year

The share option outstanding at the end of the year had a weighted average exercise price of Rs. 84.03 (31 March 2021 : Rs 84.77) and weighted average remaining contractual life of 3.82 years (31 March 2021: 3.50 years).

E. Pursuant to Share Purchase Agreement (SPA) entered between Agnus Holdings Private Limited and other promoters and CA Harbor Investments (Carlyle Group), Carlyle Group has acquired 53.02% shareholding of the holding company and has been classified as promoter of the holding company. The transfer of control to Carlyle Group has resulted into following events-

(a) Accelerated vesting of unvested employee stock options and accordingly during the previous year the Company had provided for this cost in the previous year on an accelerated basis amounting to ₹ 18.13 and

(b) The Company during the previous year, had announced a one-time bonus to the existing employees not covered by ESOP Scheme of ₹ 6.22.

The above expenses have been disclosed as exceptional items in the last financial year.



47 Financial Instruments

The carrying value and fair value of financial instruments by categories are as follows:

Financial assets	Carrying value and fair value	
	31 March 2022	31 March 2021
Measured at amortised cost		
Loans	1,756.79	1,254.19
Trade receivables	1,064.01	837.11
Cash and cash equivalents	26.09	13.54
Other bank balances	16.37	21.17
Other financial assets	22.46	101.86
Investment in a subsidiary	3,682.00	3,562.63
Measured at fair value through profit or loss (FVTPL)		
Foreign exchange forward contracts at FVTPL	2.76	0.62
Total	6,570.48	5,791.12
Financial liabilities		
Measured at amortised cost		
Borrowings (including current maturity of long term borrowings)	3,166.91	2,589.54
Trade payables	762.70	713.90
Lease liabilities	105.57	123.15
Other financial liabilities	22.69	18.16
Measured at fair value through profit or loss (FVTPL)		
Foreign exchange forward contracts at FVTPL	-	-
Total	4,057.87	3,444.75

47.1 Fair value hierarchy

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

The following table presents the fair value measurement hierarchy of financial assets and liabilities measured at fair value on recurring basis as at 31 March 2022 and 31 March 2021:

	Date of valuation	Total	Fair value measurement using		
			Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Financial assets / (liabilities) measured at fair value:					
Derivative financial assets designated at fair value through profit or loss (note 30 and 15 respectively):					
Foreign exchange forward contracts- USD	31 March 2022	2.76	-	2.76	-
Foreign exchange forward contracts- USD	31 March 2021	0.62	-	0.62	-

There have been no transfers among Level 1, Level 2 and Level 3 during the year.

Notes:

(i) Refer note 2 (xi) under significant accounting policies for recognition and measurement of financial assets.

(ii) Derivative financial instruments are valued based on quoted prices for similar assets and liabilities in active markets or inputs that are directly or indirectly observable in the market place.



47.2 Financial risk management objective and policies

The Company's principal financial liabilities comprise loans and borrowings, trade payables and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include investments, loans, trade and other receivables, and cash and deposits that derive directly from its operations.

The Company is exposed to the following risks from its use of financial instruments:

- Credit risk
- Liquidity risk
- Market risk

This note presents information about the Company's exposure to each of the above risks, the Company's objectives, policies and processes for measuring and managing risk, and the Company's management of capital. Further quantitative disclosures are included throughout these financial statements.

Risk management framework

The Company's activities makes it susceptible to various risks. The Company has taken adequate measures to address such concerns by developing adequate systems and practices. The Company's overall risk management program focuses on the unpredictability of markets and seeks to manage the impact of these risks on the Company's financial performance.

The Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework.

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to develop a disciplined and constructive control environment in which all employees understand their roles and obligations.

47.3 Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations resulting in a financial loss to the Company. Credit risk arises principally from trade receivables. Credit risk arises from cash held with banks and financial institutions, as well as credit exposure to customers, including outstanding accounts receivable. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets. The company assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors.

The credit risk on liquid funds and derivatives financial instruments is limited because the counterparties are banks with high credit-ratings assigned by credit-rating agencies.

The Company's trade and other receivables are actively monitored to review credit worthiness of the customers to whom credit terms are granted and also avoid significant concentrations of credit risks.

Given below is ageing of trade receivable spread by period of six months:

	As at 31 March 2022	As at 31 March 2021
Outstanding for more than 6 months	16.31	9.33
Others	1,047.70	827.78
	1,064.01	837.11

The Company continuously monitors defaults of customers and other counterparties, identified and incorporates this information into its credit risk controls.

The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating.

Trade receivables consist of a large number of customers spread across diverse industries and geographical areas. Ongoing credit evaluation is performed on the financial condition of accounts receivable and where appropriate, credit guarantee insurance cover is purchased for export customers.

There is no revenue from single external customer more than 10% of Company's total revenue for the year ended 31 March 2022.

In addition, the Company is exposed to credit risk in relation to financial guarantees provided by the company. The company's maximum exposure in this respect is the maximum amount the company may have to pay if the guarantee is called on. As at 31 March 2022, an amount of Rs.1,944.06 (31 March 2021 : Rs. 1,252.61) is outstanding as financial guarantee. These financial guarantees have been issued to banks and other parties with whom loan agreements have been entered by the subsidiary and parent Company.

47.4 Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company has an appropriate liquidity risk management framework for the management of short, medium and long term funding and liquidity management requirements. The Company manages liquidity risk by maintaining adequate cash reserves, banking facilities and reserve borrowing facilities by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The Company's treasury department is responsible for managing the short term and long term liquidity requirements of the Company. Short term liquidity situation is reviewed daily by Treasury. Long term liquidity position is reviewed on a regular basis by the Board of Directors and appropriate decisions are taken according to the situation.

Typically the Company ensures that it has sufficient cash on demand to meet expected operational expenses for a period of 60 days, including the servicing of financial obligations; this excludes the potential impact of extreme circumstances that cannot reasonably be predicted, such as natural disasters.

The table below provides details regarding the contractual maturities of significant financial liabilities as at 31 March 2022 and 31 March 2021:

	As at 31 March 2022			
	Total	Less than 1 year	1-2 years	2 years and above
Borrowings (including current maturity of long term borrowings)	3,166.91	738.04	-	2,428.87
Trade payables	762.70	762.70	-	-
Lease liability	105.57	4.15	5.13	96.29
Other financial liability	22.69	22.69	-	-
Financial guarantee	1,232.92	-	-	-
Total	5,290.79	1,527.58	5.13	2,525.16
	As at 31 March 2021			
	Total	Less than 1 year	1-2 years	2 years and above
Borrowings (including current maturity of long term borrowings)	2,589.54	381.73	0.51	2,207.30
Trade payables	713.90	713.90	-	-
Lease liability	123.15	4.09	5.18	113.88
Other financial liability	18.16	18.16	-	-
Financial guarantee	1,252.61	-	-	-
Total	4,697.36	1,117.88	5.69	2,321.18



47.5 Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

The Company is exposed to interest rate risk arises mainly from debt. The company is exposed to interest rate risk because the fair value of fixed rate borrowings and the cash flows associated with floating rate borrowings will fluctuate with changes in interest rates.

The Company is also exposed to foreign currency risk on certain transactions that are denominated in a currency other than the respective entity's functional currency; hence exposures to exchange rate fluctuations arise. The risk is that the functional currency value of cash flows will vary as a result of movements in exchange rates.

a) Derivative financial instruments

Derivative transactions are undertaken to act as economic hedges for the Company's exposures to various risks in foreign exchange markets and may / may not qualify or be designated as hedging instruments.

(i) Outstanding forward exchange contracts entered into by the Company as on 31 March 2022

Currency	Amount		Buy / Sell	Cross currency
	As at 31 March 2022	As at 31 March 2021		
USD	7.00	-	Sell	
USD	-	1.40	Buy	

Foreign currency Risk:

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The company's exposure to the risk of changes in foreign exchange rates relates primarily to the company's operating activities (when revenue or expense is denominated in a foreign currency).

The Company manages its foreign currency risk by hedging transactions that are expected to occur within a maximum 12-month period for hedges of forecasted sales.

b) Foreign currency risk exposure from financial instruments are given below:

Foreign currency	31 March 2022		31 March 2021	
	Receivable / (payable)	Receivable / (payable) in foreign currency	Receivable / (payable)	Receivable / (payable) in foreign currency
EURO	34.19	0.40	22.39	0.26
USD	2,646.94	34.92	1,963.70	26.72
EURO	(17.53)	(0.21)	(16.36)	(0.19)
USD	(204.85)	(2.70)	(397.66)	(5.41)
CAD	(0.06)	(0.00)	(0.03)	(0.00)
Net Exposure	2,458.68		1,572.04	

c) Foreign currency sensitivity analysis

The Company is mainly exposed to currency fluctuation of USD and Euro.

The following table details the Company's sensitivity to a 10% increase and decrease in the INR against the relevant foreign currencies. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for 10% change in foreign currency rates. A positive number below indicates an increase in profit or equity where the INR strengthens 10% against the relevant currency. For a 10% weakening of the INR against the relevant currency, there would be a comparable impact on the profit or equity, and the balance below would be negative.

10% Increase in foreign currency	Impact in the statement of profit and loss and total equity	
	As at	As at
	31 March 2022	31 March 2021
Euro (Currency of Europe)	1.67	0.60
USD (Currency of U.S.A)	244.21	156.60
Others	-*	-*

10% decrease in foreign currency	As at	As at
	31 March 2022	31 March 2021
	Euro (Currency of Europe)	(1.67)
USD (Currency of U.S.A)	(244.21)	(156.60)
Others	-*	-*

In management's opinion, the sensitivity analysis is unrepresentative of the inherent foreign exchange risk because the exposure at the end of the reporting period does not reflect the exposure during the year.

* Represents value lower than Rs.10,000.



47.6 Financial instrument - risk exposure and fair value**Interest rate risk exposure**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's long-term debt obligations with floating interest rates

At the reporting date, the interest rate profile of the Company's interest-bearing financial instruments are as follows:

	As at 31 March 2022	As at 31 March 2021
Fixed-rate instruments		
Financial assets		
-Margin money deposit	16.76	21.17
	<u>16.76</u>	<u>21.17</u>
Financial liabilities		
-Borrowings from others	-	1.28
	<u>-</u>	<u>1.28</u>
Variable-rate instruments		
Financial liabilities		
-Borrowings from bank	738.04	380.96
-Borrowings from others	2,428.87	2,207.30
Total	<u>3,166.91</u>	<u>2,588.26</u>

Interest rate sensitivity analysis for variable-rate instruments

A change of 100 basis points in interest rates at the reporting date would have increased / (decreased) equity and profit and loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency rates, remain constant.

Effect	Profit and Loss	
	100 bps increase	100 bps decrease
31 March 2022		
Variable-rate instruments	(31.67)	31.67
	<u>(31.67)</u>	<u>31.67</u>
31 March 2021		
Variable-rate instruments	(25.88)	25.88
	<u>(25.88)</u>	<u>25.88</u>

47.7 Capital management

For the purpose of Company's capital management, capital includes issued equity capital and all other equity reserves attributable to the equity share holders of the Company. The primary objective of the Company's capital management is to maximise the shareholder value.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings less cash and cash equivalents

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. As at 31st March 2022, there is no breach of covenant attached to

The Company manages its capital to ensure that entities in the company will be able to continue as going concerns while maximising the return to stakeholders through the optimisation of the debt and equity balance.

The capital structure of the Company consists of net debt (offset by cash and bank balances) and total equity of the Company.

The Company's gearing ratio is as follows :

	As at 31 March 2022	As at 31 March 2021
(i) Debt	3,166.91	2,589.54
(ii) Cash and cash equivalents	26.09	13.54
(iii) Other bank balances (Margin Money)	16.37	21.17
(iv) Current investment	-	-
Net debt [(i) - { (ii)+(iii)+(iv) }]	<u>3,124.45</u>	<u>2,554.83</u>
Total equity	<u>5,228.14</u>	<u>4,952.25</u>
Gearing ratio	<u>59.76%</u>	<u>51.59%</u>

Notes

(i) Debt is defined as long-term (including current maturity of long-term borrowings excluding financial guarantee contracts) and short-term

(ii) Gearing ratio : Net debt / Equity.



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

48 Leases

Detailed list and movement of the assets (Refer note 3.b.)

Set out below are the carrying amounts of lease liabilities (included under financial liabilities) and the movements during the period:

	Year ended 31 March 2022	Year ended 31 March 2021
As at 1 April	123.15	126.29
Deletions	(13.67)	-
Accretion of interest (Refer Note 33)	11.95	12.63
Payments	(15.86)	(15.77)
As at 31 March	105.57	123.15
Current	4.15	4.09
Non-current	101.42	119.06

The effective interest rate for lease liabilities is 10.5%.

Impact on statement of profit and loss decrease in profit for the year

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
Depreciation and amortisation expenses	12.45	12.73
Other expenses	2.20	0.29
Finance costs	11.95	12.63
Net decrease in profit for the year	26.60	25.65

Maturity Analysis of Lease (Refer Note 47.4)

Impact on the statement of cash flows increase / (decrease)


	Year ended 31 March 2022	Year ended 31 March 2021
Payment of principal portion of lease liabilities	(3.91)	(3.14)
Payment of interest portion of lease liabilities	(11.95)	(12.63)
Net cash flows from financing activities	(15.86)	(15.77)



Alivira Animal Health Limited
Notes to the financial statements for the year ended 31 March 2022
All amounts are in Rs. million unless otherwise stated

49 Ratio analysis and its elements

Sr. No.	Ratio	Numerator	Denominator	As at 31 March 2022	As at 31 March 2021	Variation	Remarks
1	Current Ratio	Current Assets	Current Liabilities	1.38	1.47	(6.1%)	
2	Debt-Equity Ratio	Total Debt	Total Equity	0.61	0.52	15.8%	
3	Debt Service Coverage Ratio	Profit after tax + Depreciation + Interest + Unrealized forex gain/ loss	Principal repayment + Lease payments	10.18	0.55	1737.7%	i) Current maturity of long term borrowing repaid in FY 21 ii) Decrease in profit year on year
4	Return on Equity Ratio	Profit after tax	Average Total Equity	0.03	0.06	(55.9%)	Decrease in profit year on year
5	Inventory turnover ratio	Sale of Product	Average Inventory	6.02	7.11	(15.2%)	
6	Trade Receivables turnover ratio	Sale of Product and service	Average Trade Receivables	5.02	4.53	10.7%	
7	Trade payables turnover ratio	Purchases	Trade Payables	5.00	4.62	8.1%	
8	Net capital turnover ratio	Sale of Product and service	Working Capital	8.03	7.52	6.8%	
9	Net profit ratio	Net profit after tax	Sale of Product and service	0.03	0.07	(59.0%)	Decrease in profit year on year
10	Return on Capital employed	Profit before tax and interest	Tangible Networth + Total Debt + Deferred Tax Liability	0.05	0.07	(27.1%)	Decrease in profit year on year
11	Return on investment	Profit before tax and interest	Total Assets	0.05	0.06	(26.7%)	Decrease in profit year on year



50 Utilization of funds

(i) Following are the details of the funds advanced by the Company to intermediaries for further advancing to the Ultimate beneficiaries:


Name of the intermediary to which the funds are advanced	Date of Funds advanced	Amount of funds advanced	Date on which funds are further advanced invested by intermediaries or Ultimate Beneficiaries	Amount of fund further advanced or loaned or invested by such intermediaries to other intermediaries or Ultimate Beneficiaries	Ultimate Beneficiary
Alivira Animal Health Limited, Ireland	27-Jul-21	16.38	28-Jul-21	16.38	Bremer Pharma GmbH
Alivira Animal Health Limited, Ireland	18-Oct-21	16.58	26-Nov-21	16.58	Bremer Pharma GmbH
Alivira Animal Health Limited, Ireland	23-Dec-21	53.52	06-Jan-22	53.52	Alivira Saude Animal Brasil Participacoes Ltda
Alivira Animal Health Limited, Ireland	10-Feb-22	48.75	01-Mar-22	48.75	Alivira Saude Animal Ltda

The Company has complied with the relevant provisions of the Foreign Exchange Management Act, 1999 (42 of 1999) and the Companies Act for the above transactions and the transactions are not violative of the Prevention of Money-Laundering Act, 2002 (15 of 2003)

(ii) Details of intermediary and ultimate beneficiary

Name of the intermediary / ultimate eneficiary	Registered Address	Government Identification Number *	Relationship with the Company
Alivira Animal Health Limited, Ireland	16 Glenoaks Cose, Glencorner, Clonmel, Co Tipperary, Ireland - E91T8Y6	548942	Wholly Owned Subsidiary
Alivira Saude Animal Brasil Participacoes Ltda	367, Rau Joao Baptista De Queiroz Junior, Jardim Myrian Morei, Campinas, SP 13098-415	35.2.2993243-5	Step down subsidiary
Bremer Pharma GmbH	Werkstr. 42 34414 Warburg Germany	HRB4902	Step down subsidiary
Alivira Saude Animal Ltda	367, Rau Joao Baptista De Queiroz Junior, Jardim Myrian Morei, Campinas, SP 13098-415	35.2.0855295-1	Step down subsidiary

* Company Identification Number



51 Transfer pricing

In respect of Transfer pricing regulations under Section 92 to 92F of the Indian Income Tax Act, 1961, the Management confirms that its international transactions and Specified Domestic Transactions are at arm's length so that the aforesaid legislation will not have any impact on the financial statements, particularly on the amount of tax expense and that of provision for tax.

52 Following outbreak of COVID-19 pandemic globally and in India, the Company has adopted measures to curb the spread of infections in order to protect health of its employees and business continuity with minimal disruption. Considering that the Company is in business of Animal Health Care which is considered to be an essential service, the Company's operations do not have any significant impact as all its plants are operating and sales are continuing. The Company's management, based on internal and external information available, has assessed its impact on carrying value of receivables and investments. The impact of the global health pandemic may be different from that estimate as at the date of approval of these financial statements and the management will continue to closely monitor any material changes to future economic condition.

53 On May 7, 2022, subsequent to the year end, there was a incident of fire at Company's API facility in Visakhapatnam, which was brought under control soon. The manufacturing activity was temporarily disrupted and the facility is adequately covered under Insurance and the claim process in ongoing.

54 The Company do not have any Benami property, where any proceeding has been initiated or pending against the company for holding any Benami property under the Benami Transactions (Prohibited) Act, 1988 and rules made thereunder.

55 There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax

56 The Company do not have any charges or satisfaction which yet to be registered with Registrar of Companies beyond the statutory period

57 The company has not traded or invested in crypto currency or virtual currency during the current or previous year.

58 The company has no transactions with struck off companies in current or previous year..

59 The Company has not been declared as wilful defaulter by any bank or financial institution or government or any government authority.

60 The quarterly returns or statements of current assets filed by the company with banks or financial institutions are in agreement with the books of accounts.

61 Previous years figures have being regrouped/reclassified wherever necessary to make them comparable.

62 The financial statements were approved for issue by the Board of Directors on 25th May 2022.

As per our report of even date

For S R B C & CO LLP
Chartered Accountants
ICAI firm registration number ; 324982E / E300003

Per Anil Jobanputra
Partner
Membership No: 110759



Mumbai, 25 May 2022

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

Rajaram Narayanan
Managing Director &
Chief Executive Officer
DIN: 02977405

Tushar Mistry
Chief Financial Officer

Sharat Narsapur
Joint Managing
Director
DIN: 02808651

Abhishek
Abhishek Joshi
Company Secretary
Membership No- A61662

